Solicited opinion/review to Nature Ageing

Autophagy in healthy ageing and disease

3 4

5 6

1

2

Yahyah Aman^{1,3†}, Tomas Schmauck-Medina^{1†}, Malene Hansen⁴, Richard I Morimoto⁵, Anna Katharina Simon⁶, Ivana Bjedov^{3,7}, Konstantinos Palikaras⁸, Anne Simonsen⁹, Terje Johansen¹⁰, Nektarios Tavernarakis^{11,12}, David C. Rubinsztein^{13, 14}, Linda Partridge^{3, 15}, Guido Kroemer¹⁶⁻²⁰, John Labbadia^{3,*} and Evandro F. Fang^{1,2,*}

7 8 9

- 10 Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital,
 11 1478 Lørenskog, Norway
- 12 ²The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway
- 13 ³Institute of Healthy Ageing, Department of Genetics, Evolution and Environment, University
- 14 College London, Darwin Building, Gower Street, London WC1E 6BT, UK.
- 15 ⁴Sanford Burnham Prebys Medical Discovery Institute, Development, Aging and Regeneration
- Program, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA.
- ⁵Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern
- 18 University Evanston, IL 60208 USA.
- 19 ⁶Kennedy Institute of Rheumatology, University of Oxford, Headington, Oxford, UK.
- ⁷UCL Cancer Institute, University College London, London WC1E 6JD, UK.
- 21 Beartment of Physiology, School of Medicine, National and Kapodistrian University of
- 22 Athens, Athens, Greece
- ⁹Department of Molecular Medicine, Institute of Basic Medical Sciences and Centre for Cancer
- Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo,
- 25 Oslo, Norway.
- ¹⁰Molecular Cancer Research Group, Institute of Medical Biology, University of Tromsø The
- 27 Arctic University of Norway, 9037, Tromsø, Norway
- ¹¹Institute of Molecular Biology and Biotechnology, Foundation for Research and
- 29 Technology-Hellas, Heraklion, Crete, Greece.
- 30 ¹²Department of Basic Sciences, School of Medicine, University of Crete, Heraklion, Crete,
- 31 Greece
- 32 ¹³Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters
- 33 Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, United Kingdom
- ¹⁴UK Dementia Research Institute, University of Cambridge, Hills Road, Cambridge CB2 0XY,
- 35 United Kingdom
- ¹⁵Max Planck Institute for Biology of Ageing, Department Biological Mechanisms of Ageing,
- 37 Cologne, Germany
- 38 ¹⁶Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer,
- 39 Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France,
- 40 Paris, France
- 41 ¹⁷Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
- 42 ¹⁸Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
- 43 ¹⁹Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou,
- 44 China
- 45 ²⁰Karolinska Institute, Department of Women's and Children's Health, Karolinska University
- 46 Hospital, Stockholm, Sweden

47

- *Correspondence: <u>e.f.fang@medisin.no</u> (E.F.F.) and <u>j.labbadia@ucl.ac.uk</u> (J.L.)
- 49 † These authors contributed equally

50

Abstract

51

52

53

54

55

56 57

58

59

60

61 62

63

64

65 66

67

68 69

70 71 72 Autophagy is a fundamental cellular process that eliminates subcellular components via lysosome mediated degradation to promote homeostasis, differentiation, development, and survival. While autophagy is intimately linked to health, the intricate relationship between autophagy, ageing and disease, remains unclear. Furthermore, the broad spectrum of substrates associated with autophagy (nucleic acids, proteins, lipids, organelles, and pathogens) raises a key question: how do distinct autophagic mechanisms influence tissue and organismal homeostasis in the long-term? This review examines several emerging features of autophagy and postulates how they may be linked to ageing as well as to the development and progression of disease. In addition, we discuss the current pre-clinical evidence arguing for the use of autophagy modulators as suppressors of age-related pathologies, such as neurodegenerative diseases. Finally, we highlight key questions and propose novel research avenues that will likely reveal new links between autophagy and the hallmarks of ageing. Understanding the precise interplay between functionally active autophagy and the risk of age-related pathologies will elucidate the ageing landscape across organisms and eventually facilitate the development of clinical applications that promote longterm health.

Keywords: autophagy; ageing; neurodegeneration; Alzheimer's disease; mitophagy; NAD+; Rapamycin; Spermidine; cGAS-STING

1. Ageing and autophagy

Ageing is a biological process that is characterised by a time-dependent cellular and functional decline, resulting in reduced quality of life for the organism¹. Consistent with this, ageing is the primary risk factor for the development of many disorders, including cardiovascular disease (e.g., stroke), cancer and neurodegenerative disease (e.g., Alzheimer's disease (AD)). Collectively, age-related ailments result in a formidable global socio-economic burden and a significant healthcare challenge^{2,3}. Therefore, identifying therapeutic interventions that promote "healthy ageing" (i.e., the maintenance of functional ability in old age, enabling the elderly to independently carry out daily tasks) and simultaneously halt the progression of multiple age-related pathological conditions, is of paramount importance².

Amongst many molecular changes associated with old age, altered autophagy has emerged as a feature of ageing across diverse species. However, recent advances in understanding the numerous substrates of autophagy, and the temporal and spatial effects of impaired autophagy regulation on tissue homeostasis, have revealed a complex and multi-factorial relationship between autophagy and ageing. Here we examine the relationship between autophagy, ageing, and disease; and propose novel links between specific autophagic processes and long-term tissue health, as well as possible implications for anti-ageing therapeutic interventions.

2. Compromised autophagy is a hallmark of ageing

Research over the last decade has revealed that the process of autophagy can take many different forms. Autophagy (from the Greek words "auto", meaning "self," and "phagein", meaning "to eat") is a highly conserved pathway that degrades cellular components, such as defective organelles and aggregates of misfolded proteins4, through the lysosomes. The process of autophagy was first described in the 1960s, but it was the identification of autophagy-related genes (ATG) in the 1990s that propelled the major breakthroughs in unravelling the mechanistic complexities of autophagy⁵⁻¹². There are three major types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA) (Fig. 1a-c), all of which involve delivery of substrates to the lysosome for degradation (detailed reviews^{13,14}). Macroautophagy (hereafter referred to as autophagy) was originally thought of as a non-selective, bulk degradation process (Fig. 1a-I). However, the discovery of selective autophagy receptors, with p62/SQSTM1 being the first, changed this notion 15,16. Today, autophagy is recognised as a highly selective cellular clearance pathway that is associated with the maintenance of cellular and tissue homeostasis 17,18. Selective autophagy can be further classified into many sub-types based on the specific cargos involved. These include various macromolecules (glycophagy, lipophagy) (Fig. 1a-II to Fig. 1a-V)), mitochondria (mitophagy) (Fig. 1a-VI), endoplasmic reticulum (ER) (ER-phagy) (Fig. 1a-VII), parts of the nucleus (nucleophagy) (Fig. 1a-VIII), pathogens (xenophagy) (Fig. 1a-IX), and lysosomes themselves (lysophagy) (Fig. 1a-X). Below, we will discuss the links between these selective autophagy pathways, ageing and disease. The core process of macroautophagy has been described in detail elsewhere 14,19. However, in brief, amongst the core autophagy process is initiated following inhibition of the mechanistic target of rapamycin (mTOR) or activation of 5' AMP-activated protein kinase (AMPK), both of which are canonical inducers of autophagy in response to stress (e.g., starvation, elevated temperatures) and physical exercise. In addition, Transcription Factor EB (TFEB) is an important positive regulator of autophagy and lysosomal biogenesis, whose nuclear translocation is coupled to the activity of both mTOR (via phosphorylation) and AMPK (via Folliculin (FLCN))²⁰⁻²³. Upon activation of autophagy, the process is initiated by membrane nucleation and phagophore formation, and elongation and maturation, are initiated, before the autophagosome fuses with the lysosome for cargo degradation and recycling. The key proteins involved in each step are presented in Fig. 2.

A growing body of evidence suggests that autophagic activity declines with age in diverse organisms¹. Studies in *Caenorhabditis elegans* (*C. elegans*), rodents, and human cells have demonstrated an age-dependent reduction in lysosomal proteolytic function, thereby impairing

autophagic flux²⁴⁻²⁷, exacerbating cellular impairment and contributing to the development of age-related diseases^{1,28,29}. Further evidence stemming from *Drosophila* has revealed that ageing is associated with the reduced expression of several Atg genes (Atg2, Atg8a, blue cheese gene / Bchs), which are pivotal for both autophagy initiation and activity³⁰. In aged wildtype (WT) mice, autophagy is diminished in neuronal cells as evidenced by decreased rates of autophagolysosomal fusion and impaired delivery of autophagy substrates to lysosomes in the hypothalamus³¹. Moreover, a decrease in autophagic processes was observed in 18–25month-old murine brain tissue, as demonstrated by a reduction in Atg5-Atg12 and Becn1 levels, elevated mTOR activity, and increased ferritin H levels (Ferritin H is mainly removed from cells by the autophagy-lysosome pathway)³². In addition, emerging findings in aged-rats have also highlighted an age-associated decline in the expression of the autophagy related protein Becn1 in whole brain tissue, as well as in the hippocampus of naked mole-rats and Wistar rats, respectively^{33,34}. Consistent with observations in rodent models, findings in humans have suggested that the expression of autophagy-related genes, such as ATG5, ATG7 and BECN1, declines with age³⁵. Moreover, the development and progression of several human pathologies is highly associated with age-dependent autophagy deficits 19,36,37. Collectively these studies demonstrate that a gradual decline in autophagy-related proteins, and reduced delivery of cargo to lysosomes, occurs with age, implicating compromised autophagy as a cardinal feature of organismal ageing.

Consistent with a causal role for autophagy in the ageing process¹⁴, genetically impairing non-selective or selective autophagy results in accelerated tissue functional decline and disease in a range of experimental models. Transcriptomic profiling in the Brewer's yeast *Saccharomyces cerevisiae*, has provided evidence for defective autophagy amongst short-lived, compared to long-lived, mutants³⁸. In addition, selective mutation(s) and/or knockdown of genes encoding proteins of the autophagic machinery in *C. elegans* (*ATG8/ lgg-1*, *ATG1/unc-51*, *bec-1*, *atg-7*, *atg-12* and *atg-18*), *Drosophila* (*Atg3* and *Atg8a*) and mice (*Atg5*, *Atg7*, and *Becn1*) shorten lifespan and healthspan^{1,14,30,39}. Consistent with these observations, the systemic genetic knockout of the autophagy components (*Becn1*, *Atg5*, *Atg9*, and *Atg13*) are lethal in mice, thereby highlighting the importance of autophagy in development⁴⁰. Furthermore, knockdown of genes encoding transcription factors that regulate autophagy, such as *TFEB* (orthologue in *C. elegans hlh-30*) and Forkhead Box O (*FOXO*; orthologue in *C. elegans daf-16*) shortened lifespan in both wild-type (WT) and long-lived *daf-2* (insulin/IGF-1 receptor) mutants⁴¹.

 In contrast, studies in long-lived mutant animals have shown that increased autophagy is associated with delayed ageing. In particular, the extended lifespan of *C. elegans daf-2* loss-of-function mutants is dependent on autophagic genes, such as *bec-1*, *lgg-1*, *atg-7* and *atg-12*^{1,14,42}. Furthermore, hlh-30/TFEB is required for the long lifespan of multiple longevity mutants, including not only *daf-2*/InR reduced insulin/insulin-like signalling mutants, but also germline-less *glp-1(e2141)* mutants, dietary-restricted *eat-2(ad1116)* mutants, mitochondrial respiration defective *clk-1(e2519)* mutants, and mRNA translation impaired *rsks-1(sv31)* mutants⁴³. These findings coincide with impaired induction of autophagosome formation and lysosomal degradation upon loss of *hlh-30/TFEB*, suggesting that HLH-30/TFEB promotes longevity by regulating the autophagy process downstream of multiple lifespan extension paradigms⁴³. In addition, the formation of long-lived dauer worms, a larval hibernation stage, is also associated with increased autophagy, and is dependent on the autophagy genes *atg-1*, *atg-7*, *lgg-1* and *atg-18*, underlining the essential role of autophagy in organismal adaptation during challenging conditions⁴².

 Consistent with observations from long-lived mutants, genetic or pharmacological upregulation of autophagy promotes longevity in animals. Autophagy induction by overexpression of *Atgs* in *Drosophila* (*Atg1* and *Atg8a*) and mice (*Atg5*) extended lifespan^{30,44,45}. Similarly, *BCL2* mutations that disrupt the BECN1-BCL2 complex, increase basal autophagic flux, which results in long-lived male and female mice with improved healthspans⁴⁶. Additionally, overexpression of autophagic regulators in *C. elegans* and *Drosophila*, such as AMPK, further

facilitates autophagy in diverse tissues, and in turn extends longevity^{14,45}. Furthermore, *hlh-30/TFEB* overexpression enhances autophagy and promotes lifespan extension in *C. elegans*⁴³, and silencing of the nuclear export protein, Exportin-1 (XPO1/XPO-1), enhances autophagy by enrichment of HLH-30/TFEB in the nucleus, which is accompanied by proteostatic benefits and improved longevity⁴⁷. Moreover, rapamycin, an inhibitor of the mTOR pathway, fed late in life, has been shown to extend the median and maximal lifespan of both female and male mice⁴⁸.

Accumulating evidence in aged mice, as well as rodent models recapitulating characteristic features of human diseases, shows that compromised autophagy is amongst the most common factors contributing to the collapse of tissue homeostasis. In particular, age-associated dysregulation of autophagy (demonstrated by the accumulation of autophagosomes), possibly due to impaired lysosomal fusion and/or degradation, is associated with cellular dysfunction and/or death, which contributes to neurodegeneration, as well as cardiac and skeletal muscle ageing⁴⁹⁻⁵³. In hematopoietic stem cells (HSC), autophagy has been shown to delay ageing via activation of downstream sirtuin-3 (SIRT3), a key mitochondrial protein capable of rejuvenating blood and protecting against oxidative stress in mice and human HSC-enriched cells⁵⁴.

Moreover, autophagy appears to be a critical mechanism to maintain immune memory in mice, and levels of the endogenous autophagy-inducing metabolite spermidine fall in human T cells with age. In fact, spermidine supplementation to T cells from old donors restores autophagy levels to that observed in young donors via the translation factor eIF5A and transcription factor TFEB⁵⁵. Furthermore, spermidine administration in a mouse model of mild cognitive impairment (MCI), a transitional phase between AD and healthy ageing, causes an improvement in degradation of misfolded proteins, and an accompanying delay in age-related memory deficits, thereby implicating autophagy as a pathophysiological mechanism of action

Whilst the dysregulation of autophagy underlies ageing and disease phenotypes, excessive autophagy may also contribute to the deterioration of cellular function in some contexts. Recent evidence demonstrates that an age-dependent decline in Rubicon, a negative regulator of autophagy, exacerbates metabolic disorders in adipocytes⁵⁷. In addition to the possibility that hyper-upregulated autophagy may exacerbate metabolic disorders, this finding may also be attributed to autophagy-independent changes in metabolism. Furthermore, elevated autophagy has been found to shorten lifespan in C. elegans mutants lacking serum/glucocorticoid regulated kinase-1 (sqk-1). The loss of sqk-1 results in increased mitochondrial permeability, leading to excessive autophagy and reduced organismal fitness in worms and mice⁵⁸. Conversely, reducing the levels of autophagy in sqk-1 mutants, or suppressing the opening of the mitochondrial permeability transition pore, restores normal lifespan⁵⁸. Similarly, suppressing autophagy exclusively in the intestine of post-reproductive adults at higher temperatures has been proposed to prevent the emergence of age-related pathologies in *C. elegans*⁵⁹. However, it should be noted that this is in direct contrast to findings in long-lived mutants, where intestinal autophagy is enhanced^{60,61}. Another study in *C. elegans* showed that siRNA-based reduction of VPS-34/BEC-1/EPG-8 autophagic nucleation complex in aged post-reproductive worms, extended lifespan, and improved neuronal integrity²⁹. However, detailed data on knockdown efficiency in aged worms, as well as an understanding of the remaining levels of neuronal autophagy are necessary to ensure accurate in-depth data interpretation. Collectively, these observations suggest that the maintenance of functional autophagy is essential for healthy cellular and organismal ageing, and that dysregulation of autophagy in either direction, whether insufficient or excessive, contributes to cellular deficits and functional organismal decline.

A summary of autophagy-related genes linked to longevity and disease is provided in **Table 1** and **Supplementary Table 1**. Furthermore, several interventions known to promote lifespan,

including dietary restriction and treatment with pharmacological agents, such as rapamycin, spermidine, and NAD⁺ precursors, require an intact autophagic machinery. In totality, these findings reinforce the notion that autophagy stimulation is necessary and sufficient to sustain organismal homeostasis and extend longevity in multiple model organisms (discussed in detail below)¹. An overview of autophagy inducers linked to enhanced longevity and improved health is presented in **Table 2**.

Together, numerous studies provide evidence that: (i) autophagy is compromised during the process of ageing; (ii) dysfunction of autophagy shortens lifespan in various experimental animal models; and (iii) promotion/restoration of autophagy contributes to lifespan and healthspan extension of diverse organisms. This suggests that autophagy is a central regulator of ageing. However, an important and fundamental question remains unanswered: How does autophagy facilitate long-term cell and tissue health?

3. The multi-faceted role of autophagy in health and ageing

3.1. Autophagy and protein homeostasis

Protein homeostasis (proteostasis) collapse is a central hallmark of ageing and disease that is characterized by the appearance of misfolded, mislocalised and aggregated proteins. While the age-related loss of proteostasis is documented in numerous tissues, age-dependent protein aggregation is strongly linked to neurodegenerative pathologies, such as AD, Parkinson's disease, Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS)^{62,63}.

Along with molecular chaperones and the ubiquitin proteasome system (UPS), autophagy is a central regulator of cellular proteostasis that operates to: (1) degrade soluble misfolded or oligomeric proteins via CMA (the selective degradation of ubiquitin-tagged protein aggregates by chaperone-assisted selective autophagy) and (2) remove bulk protein aggregates by macroautophagy^{13,19,64}. Consistently, genetic perturbation of core components or regulators of the autophagy machinery accelerates age-related protein aggregation, shortens lifespan, and exacerbates pathological features in worm, fly and mouse models of disease. Conversely, increasing autophagy, genetically or pharmacologically, suppresses protein aggregation and promotes health and longevity^{48,65,66} (and reviewed by ⁶⁷⁻⁶⁹).

In *C. elegans,* loss of function mutations in *Beclin/bec-1* or *WIPI2/atg-18,* or RNAi against *bec-1, atg-9* or *ATG8/lgg-1,* increases susceptibility to protein aggregation, accelerates the onset of age-related paralysis and shortens lifespan^{39,70}. Similarly, mutations in the core autophagy components *atg8* or *atg7* in *Drosophila,* increase the levels of insoluble protein aggregates and reduce longevity^{30,71}. Finally, knockout of *ATG5* or *ATG7* in mouse neurons leads to the appearance of cytoplasmic inclusion bodies in the brain and early onset neurodegeneration⁷²⁻⁷⁴, while knockout of LAMP2A (the primary receptor for CMA) in the liver, results in altered proteostasis and hepatic dysfunction with age⁷⁵.

Conversely, enhanced proteostasis and extended lifespan in *C. elegans* occurs when the lysosome-autophagy transcription factor TFEB/HLH-30, or the selective autophagy receptor, p62/SQSTM-1, are upregulated. Likewise, in *Drosophila*, overexpression of Ref(2)P (p62 orthologue) or the autophagy activator, FOXO, reduces protein aggregation in various tissues and extends lifespan^{43,76-79}. Pharmacological (e.g., clonidine, rilmenidine and rapamycin) and genetic (e.g., *atg5*) upregulation of autophagy in zebrafish, harbouring the rare tau variant p.A152T, ameliorates tau pathology⁸⁰. Increased autophagy is also associated with enhanced clearance of protein aggregates in mammals, as systemic overexpression of *Atg5*, or *Becn1* mutations that disrupt BECN1-BCL2 binding, improves proteostasis and promotes longevity in mice ^{44,81}, while overexpression of the selective autophagy mediator, BAG3, suppresses tau accumulation in neurons⁸².

As a complement to the genetic modulation of autophagy, treatment of *Drosophila* with the mTOR inhibitor rapamycin, suppresses age-related protein aggregation and extends lifespan

in an autophagy-dependent manner⁸³. Furthermore, in cell culture and fly models, rapamycin suppresses toxicity associated with neurodegenerative disease-associated proteins, including mutant huntingtin, polyalanine expansion proteins and tau⁸⁴. Several other pharmacological autophagy-inducers, such as spermidine and nicotinamide, have also been reported to protect against proteostasis collapse and proteotoxicity in various models of HD, AD, PD and ALS⁶⁷.

Autophagy has also been linked to stem cell function, with the autophagy-mediated clearance of protein aggregates central to the activation of quiescent neuronal stem cells. Activating autophagy by overexpression of TFEB, or rapamycin supplementation, inhibits age-related protein aggregation and enhances neuronal and muscle stem cell function in aged mice ⁸⁵⁻⁸⁷. Given the fact that stem cell exhaustion is intimately linked to age-related tissue dysfunction, these findings suggest that enhancing proteostasis specifically in stem cells may preserve many aspects of healthy tissue function during ageing. Collectively, these observations strongly support the notion that autophagy promotes healthy ageing by protecting cells against toxic misfolded and aggregated proteins.

3.2. Autophagy regulation of macromolecule availability

Another important role for autophagy in cellular homeostasis and organismal ageing is to ensure the availability of metabolites, including amino acids, lipids, carbohydrates and nucleic acids, especially during states of stress, such as nutrient starvation (**Fig. 1a**). Under challenging conditions, autophagy promotes cellular metabolism and survival by recycling amino acids, which are generated from the degradation of cytosolic substrates, to replenish nutrients, produce energy and promote protein synthesis. The inability to properly recycle amino acids through autophagy is linked to growth and developmental defects in *Atg5* deficient mice, and impaired growth during nitrogen starvation in *atg*-deficient yeast⁸⁸⁻⁹⁰. Autophagy can also be tailored to mediate the availability of carbohydrates, lipids and nucleic acids through three main cellular processes: glycophagy, lipophagy and RNA/DNA-phagy, respectively.

3.2.1. Glycophagy

Glucose is the primary energy source for cellular metabolism. It is stored as glycogen, and metabolism of glucose is tightly regulated in a tissue-dependent manner (i.e., liver: maintain blood glucose level; muscle: source of cellular energy). However, various conditions resulting in metabolic stress, such as starvation, stimulate glycogen breakdown in order to augment cellular glucose levels and promote metabolic activity⁹¹. Glycogen can be degraded in the cytosol through the activity of glycogen phosphorylase and glycogen debranching enzymes (detailed in⁹²), or in the lysosome via autophagy. The selective clearance of glycogen via autophagy, referred to as glycophagy, plays a crucial role in glucose homeostasis. In response to nutrient-deficiency, the energy sensor AMPK is activated, which in turn inhibits the mTOR complex 1 (mTORC1), leading to activation of the ULK1 kinase, which is important for induction of autophagy (AMPK-mTORC1-ULK1 triad)⁹¹. Recent findings in yeast demonstrated that Atg11 is necessary to facilitate the interaction between AMPK homolog Snf1 with ULK1 homolog Atg1 upon glucose starvation to promote autophagy⁹³. The LC3-interacting region (LIR) motif, also known in yeast as Atg8 family interacting motif (AIM), in starch-binding domain-containing protein 1 (STBD1) may allow cells to physically link glycogen to GABARAPL1, facilitating the transport of glycogen to lysosomes for degradation (Fig. 1a-III)94. In parallel to glycophagy, other pathways, such as β-oxidation, may maintain cellular bioenergetics to compensate for glucose deprivation⁹⁵. Autophagy also plays a pivotal role in maintaining cell function, not only in glucose starvation, but also in conditions of excess glucose. High glucose levels were associated with mitochondrial dysfunction, generation of reactive oxygen species (ROS), and induction of autophagy in endothelial progenitor cells (EPCs)⁹⁶.

Under conditions of impaired autophagy, the accumulation of glycogen contributes to the pathogenesis of age-related diseases. Pompe disease, a lysosomal storage disorder has an impaired ability of the lysosome to degrade glycogen, due to deficiency in the lysosomal

hydrolytic enzyme acid α-glucosidase (GAA). This results in accumulation of lysosomal glycogen in many tissues, predominantly in skeletal and cardiac tissues, leading to progressive lethal skeletal myopathy, respiratory and cardiac defects⁹⁷. Impaired tissue function results from an inability of the lysosome to degrade glycogen leading to energy deficiency in skeletal muscle. For infantile-onset Pompe disease⁹⁸, a promising therapeutic intervention is administration of recombinant human GAA. Furthermore, dysfunctional autophagy-mediated accumulation of glycogen has been demonstrated to be the cause of neurodegeneration in a mouse model of Lafora disease, which is suppressed when glycogen synthase is deleted⁹⁹. These findings indicate that glycogen accumulation might be a cause, rather than a consequence, of impaired autophagy, resulting in impaired cellular function and disease. Glycophagy, therefore, is essential for cellular function and survival, suggesting that levels of glycophagy could determine organismal health, and possibly longevity.

3.2.2. Lipophagy

The intracellular storage and utilization of lipids are critical to maintain cellular energy homeostasis. In response to starvation, triglycerides stored in lipid droplets are hydrolysed by specific lipases into free fatty acids for energy metabolism. Lipid droplets can also undergo selective degradation by autophagy, termed lipophagy, as an alternative mechanism for regulating lipid homeostasis (Fig. 1a-IV)¹⁰⁰. To date, a specific receptor coupling lipid droplets to autophagosomes, and trafficking to lysosomes, has not yet been identified, although LC3mediated engulfment of lipid droplets has been observed¹⁰¹. Moreover, CMA has been implicated in degradation of the lipid droplet-associated proteins perilipin 2 (PLIN2) and perilipin 3 (PLIN3)102. The lysosomal acid lipases are involved in the degradation of lipid droplets; in particular, lipolysis is conducted primarily by adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), and selective knockdown of ATGL and HSL in mice results in selective inhibition of lipid droplet degradation, whilst other autophagy processes (i.e., degradation of proteins and organelles) serve as a compensatory mechanism to replenish the reduced availability of energy substrates 103. An age-dependent decline in basal autophagy in the liver may underlie the accumulation of hepatic lipids, which in turn has been proposed to contribute to metabolic conditions as well as impairing autophagy, a vicious cycle promoting ageing¹⁰⁰. For example, the age-dependent reduction of CMA is likely due to alterations in the lipid composition of discrete microdomains at the lysosomal membrane, including altered dynamics and stability of the CMA receptor, LAMP-2A, in the lysosome 104. Additional mechanisms by which age-related alterations in lipid composition and/or levels may impair autophagy, remain unknown. Further, age-dependent accrual of lipid droplets and ectopic fat deposition are highly interconnected with the age-dependent decline of autophagy and/or autophagic defects 105,106. Autophagy and LIPL-4/hLAL-dependent lipolysis are both upregulated in germline-less *C. elegans*, and work interdependently to prolong lifespan¹⁰⁷. The mammalian homologue of the worm LIPL-4 is lysosomal acid lipase (LIPA), a key enzyme involved in the hydrolysis of cholesterol via autophagy^{108,109}. Cellular supplementation with NAD+, which stimulates autophagy and subtypes of autophagy, including mitophagy, and stimulates the activity of the NAD+-dependent SIRT1 and SIRT3 pathways, reduced fat accumulation and increased lifespan in high-fat fed and progeroid animals 110-112, highlighting the importance of autophagic degradation of lipids in healthspan and lifespan.

In pathological conditions, such as alcoholic fatty liver disease (AFLD), impaired lipophagy has been shown to be the basis of lipid peroxidation and cellular damage. AFLD results from excessive consumption of alcohol, leading to damage caused to the liver in the form of oxidative stress, excessive lipid droplet accumulation in the cytoplasm of hepatocytes (steatosis), mitochondrial damage and cell death. Acute exposure to ethanol triggers lipophagy, which acts as a defence mechanism against lipid peroxidation, thereby protecting hepatocytes. However, chronic exposure to ethanol leads to mTOR-mediated inhibition of lipophagy, which in turn, contributes to lipid peroxidation and cell death^{22,113,114}. In fact, inhibition of mTOR-mediated suppression of TFEB, using torin-1, resulted in enrichment of TFEB levels in the liver and protection against steatosis and ethanol-induced liver injury¹¹⁵.

Genetic overexpression of TFEB in the liver was shown to increase lysosomal biogenesis and mitochondrial bioenergetics, which served as a protective mechanism against ethanol-induced liver injury in mice. In line with these findings, knockdown of TFEB in the liver of mice resulted in more severe liver injury in response to increased ethanol consumption 115 . In addition, lipophagy is key for the differentiation of several cell types, including hepatocytes 116 and neutrophils 117 . Knocking out Atg7 in hematopoietic stem cells leads to an accumulation of immature neutrophils resembling the myeloid bias of an aging hematopoietic system. Their differentiation can be rescued by exogenous free fatty acids used for β -oxidation, further demonstrating that lipophagy usually provides these during the energy intensive process of differentiation. Further studies on the molecular mechanisms of lipophagy, including identification of lipid-specific autophagy receptors, and their impact on cellular homeostasis, will shed light on the relationship between autophagy, metabolism, and ageing.

3.2.3. Autophagic degradation of nucleic acids: RNAs (RNautophagy / RNAphagy) and DNAs (DNautophagy / DNAphagy)

Nucleic acids are degraded via multiple mechanisms (the complete description of which is beyond the scope of this review (see details in 118,119)), including autophagy. RNA/DNA are targeted for lysosomal degradation via several pathways, including Atg8/LC3-dependent autophagic degradation of stress granules (condensates of proteins and RNAs)¹²⁰, p62 and NDP52-dependent autophagic degradation of retrotransposon RNA¹²¹, lysosomal membrane protein LAMP2C-dependent direct binding to RNA (also for DNA¹²²) for lysosomal degradation¹²³, and a lysosomal putative RNA/DNA transporter, SIDT2 (SID1 transmembrane family, member 2)-that mediates direct uptake of RNA (and DNA¹²⁴) for lysosomal degradation¹²⁵. At present, little is known about whether, and how, RNAphagy and DNAphagy affect health and ageing. However, it is reasonable to suggest that nucleic acid turnover is essential for health, as accumulation of damaged or unnecessary DNA and RNA in the cytosol promotes inflammation, cancer and even accelerated ageing 68,126,127. DNA damage triggers autophagy and subtypes of autophagy that are considered as cell survival responses¹²⁸; however, genetic or age-dependent impairment of DNA repair leads to genomic instability, cellular dysfunction, cell death and accelerated ageing⁶⁸. Exogenous DNA or RNA (e.g. microbial) or endogenous nuclear or mitochondrial DNA in the cytoplasm may trigger autophagy. Nuclear DNA (including extranuclear chromatin) could be aberrantly released into the cytoplasm due to impaired nuclear envelope integrity, nuclear envelope blebbing, or nuclear export processes 129; mitochondrial DNA could leak into the cytoplasm due to mitochondrial damage and inefficient elimination of damaged mitochondria via mitophagy^{126,127}. The cyclic GMP-AMP (cGAS)-stimulator of interferon genes (STING) or RIG-I/ MAVS signalling axis detects these nucleic acid fragments to initiate an innate immune reaction, linking it to autoimmunity, inflammation, senescence, and autophagy¹²⁹. Collectively, genomic instability, accumulation of mitochondrial DNA leakage into the cytoplasm, and increased levels of cellular stress granules, are linked to inflammation, accelerated ageing and a broad range of neurodegenerative diseases 120,121,126. Although maintenance of DNA/RNA homeostasis is critical for healthy ageing, the contribution of RNAphagy and DNAphagy to long-term tissue health and pathology requires further exploration.

3.3. Autophagy of sub-cellular organelles: mitophagy, ER-phagy, nucleophagy, lysophagy

Ageing is associated with an accumulation of damage to subcellular organelles. The timely and efficient disposal and recycling of dysfunctional organelles is necessary to maintain cellular function and viability. Selective autophagy is the common mechanism underlying the clearance of sub-cellular damaged and/or superfluous organelles, such as, mitochondria (mitophagy), endoplasmic reticulum (reticulophagy or ER-phagy), nucleus (nucleophagy) and lysosomes (lysophagy)¹⁷. Both membrane-bound and soluble selective autophagy receptors are involved in the selective organelles degradation^{18,130}.

Among the different types of autophagy targeting sub-cellular organelles, the most investigated is mitophagy. Mitophagy is the selective autophagic elimination of defective or surplus mitochondria. The PINK1-PARKIN mediated pathway for degradation of heavily depolarised mitochondria is best understood and involves Ser-65 phosphorylated ubiquitin that attracts soluble selective autophagy receptors NDP52, optineurin and p62, which then recruit the core autophagy machinery for autophagosome formation on the damaged mitochondria¹³¹. In addition, other basal-, developmental or stress-induced mitophagy pathways involve binding of LC3 to a series of LIR-containing mitochondrial outer membrane proteins, such as NIX (BNIP3L), BNIP3, FKBP8, FUNDC1, BCL2L13, PHB2, AMBRA1 and also Atg8/LC3-binding mitochondrial lipids like cardiolipin³⁷ (Fig. 1a-VI, left). While whole mitochondria can be degraded via mitophagy, it appears that organelles with minor damage can be 'repaired' by other quality control mechanisms such as the piecemeal mitophagy pathway, which is a basal housekeeping mitophagy pathway that involves degradation of mitochondrial proteins in an LC3C- and p62-dependent manner¹³² (Fig. 1a-VI, right). In addition, other mitochondrial degradation pathways include the mitochondria-derived vesicle (MDV) pathway, where damaged cargo (e.g., impaired mitochondrial proteins) are delivered to the lysosome for degradation in a process dependent on Syntaxin-17, PINK1 and Parkin¹³³. A recent study in C. elegans shows that damaged subcellular components, including mitochondria among others, can be budded off from certain neurons via membrane-bound vesicles (termed 'exophers')134. Once in the extracellular space, these damaged organelles can be engulfed and digested by surrounding cells¹³⁴. This cellular release of 'exophers' is also conserved in mammals, as cardiomyocytes release exophers (containing mitochondria) to be received and eliminated by adjacent macrophages¹³⁵.

457

458 459

460

461

462 463

464

465

466

467

468 469

470 471

472

473

474

475

476

477 478

479

480 481

482

483

484

485

486

487 488

489

490

491 492

493

494

495 496

497

498

499

500

501

502

503 504

505

506

507508

509

510

511

Accumulating evidence highlights that mitophagy is a critical contributor to cellular physiology and organ homeostasis. First, there is an increase of mitophagy from juvenile to adulthood, followed by a dramatic reduction in old animals. For example, there is an increase of basal mitophagy in fly flight muscle from the ages of 1 week to 4 weeks¹³⁶; in mice, mitophagy in the dentate gyrus (DG), a region that is essential for memory, was reduced by approximately 70% between 3 and 21-months of age¹³⁷. Mitophagy is also impaired in high-fat feeding conditions¹³⁷ and in neurodegenerative diseases (reviewed in³⁷). Indeed, mitophagy is reduced in mice with AD (by approximately 50% in the hippocampus vs. healthy controls)¹³⁸, PD (reviewed in 139) and HD (by over 70% in the DG region of HTT expressing mice versus WT controls)¹³⁷. Second, intact mitophagic machinery is required for longevity. Since there are several redundant mitophagy pathways, dysfunction of isolated individual mitophagy pathways may not affect lifespan ^{140,141}. However, mitophagy is essential for longevity under conditions of low insulin/IGF-1 signalling (C. elegans daf-2 mutants) and dietary restriction (C. elegans eat-2 mutants)140,142, as well as for the maintenance of neuronal functions in response to stressful conditions 126. Third, mitophagy induction is sufficient to improve healthspan and extends lifespan in several model organisms, rescues age-associated neurodegenerative phenotypes in AD138,143 and prolongs lifespan in nematode and fly models of accelerated ageing 66,111,144. Moreover, functional mitophagy is essential for restraining innate immunity, as mitochondrial stress can lead to the release of damage-associated molecular patterns (DAMPs) that activate innate immunity. Inflammation resulting from excessive exercise in Pink1 and Parkin knockout mice has been shown to be suppressed by loss of STING, a central regulator of the type I Interferon response to cytosolic DNA¹²⁶.

Other autophagic pathways that target subcellular organelles include ER-phagy, nucleophagy, and lysophagy. In yeast, Atg39 regulates perinuclear ER-phagy and nucleophagy, while Atg40 is necessary for cortical/cytoplasmic ER-phagy¹⁴⁵ (**Fig. 1a-VII**). ERphagy is conserved in mammalian cells through specific ERphagy receptors, such as FAM134B, SEC62, RTN3L, CCPG1, ATL3 and TEX264 (reviewed in¹⁴⁶). Nucleophagy is conserved in mammalian cells¹⁴⁷ with a nuclear LC3B-lamin B1 interaction-based nuclear-to-cytoplasmic degradation, which may be a guarding mechanism protecting cells from tumorigenesis¹⁴⁸ (**Fig. 1a-VIII**). Lysophagy is regulated by both ubiquitin-dependent (Galectin-3-TRIM16-ULK1/ATG16L-autophagy

receptor-LC3, the F-box protein FBXO27 and UBE2QL1) as well as -independent (Galectin-8-autophagy receptor-Atg8/LC3) pathways (reviewed in¹⁴⁹) (**Fig. 1a-X**). Maintenance of functional and effective lysosomes, via timely and efficient lysophagy, is essential for cell survival. In particular, dysfunction in lysosomal membrane proteins such as SCAV-3, the *C. elegans* homolog of human LIMP-2, has been linked to reduced lifespan, implicating lysosome integrity as a defining factor of longevity^{150,151} ²⁵. Moreover, dysfunctional lysosomal membrane proteins coupled to leakage of proteolytic enzymes (i.e., cathepsin D) into the cytosol has been associated with ageing, and pathological ageing, in a broad range of neurodegenerative diseases¹⁵². Thus, maintaining physiological lysophagy is critical for many cellular processes and is presumably important for health and longevity, as lysosomal rupture triggers endolysosomal damage responses, and even lysosomal cell death, which links to ageing and diseases^{152,153}.

Collectively, imbalanced quality surveillance system of sub-cellular organelles, such as mitochondria, ER, small nuclear fractions, and lysosomes, might be a causative factor for age-related pathologies as well as premature ageing. Further studies on mitophagy, ER-phagy, nucleophagy, and lysophagy to decipher their multi-layer regulatory network, and their association with ageing and health, are necessary. In particular, studies to address how these processes change with age, and how they influence age-related tissue function, will lead to critical insights with broad relevance to human health and quality of life.

3.4 Xenophagy

Xenophagy (from the Greek meaning "to eat foreign matter") is the process by which autophagy targets pathogens¹⁵⁴. Many pathogens are known to be degraded by autophagy, while others take over core autophagy components for their own benefit¹⁵⁵ (**Fig. 1a-IX**). Indeed, several studies have revealed that autophagy can target bacteria like *Rickettsia conorii*¹⁵⁶, *Listeria monocytogenes*¹⁵⁷ *Streptococcus pyogenes*¹⁵⁸, and *Mycobacterium tuberculosis*^{159,160}. Xenophagy may also protect the body against invasion by viruses and parasites.

Upon intake by inhalation, alveolar macrophages capture Mycobacterium tuberculosis. However, this bacterium has evolved to be able to impair phagosome maturation (which in normal conditions would lead to phagocytosis), and ends up hijacking the macrophage¹⁶¹. Later on, using ESX-1 (6 kDa early secretory antigenic target/ESAT-6 secretion system 1) secretions, the bacterium is able to break free from the phagosome and enters the cytosol. Here, xenophagy comes into action. cGAS detects the bacterial DNA¹⁶², which results in ubiquitination of the invading bacteria by Smurf1 (or Parkin)¹⁶³. NBR1 (or p62) attaches to these ubiquitin chains, resulting in the recruitment of ATG8/LC3B, and finally autophagic degradation occurs¹⁶⁴. Indeed, the absence of autophagic machinery components namely, ULK1¹⁶⁵, BECN1/Beclin-1¹⁶⁶, p62¹⁶⁷, ATG7¹⁶⁸ and TBK1¹⁶⁷ may promote the proliferation of the bacterium. The mechanism is similar for specific viruses. BECN1/Beclin-1, p62, and selective autophagy of viral capsids can be protective against Sindbis virus 169,170. However, other viruses, such as herpes simplex virus type 1, have evolved to inhibit autophagy by targeting BECN1¹⁷¹. In addition, several studies have highlighted the importance, and possible therapeutic relevance, of autophagy for controlling SARS-CoV-2, the coronavirus that causes COVID-19 ¹⁷²⁻¹⁷⁴. Regarding parasites, autophagy can control *Toxoplasma gondii*. Knockout of ATG5, ATG7 or ATG16L1 renders mice more likely to succumb to parasites¹⁷⁵. A detailed review between parasites and autophagy is available 176.

Although there is not much data available on a direct link between xenophagy and ageing or lifespan, it is conceivable that blocking the infection of exogenous intruders is required for maintenance of a healthy state and reduced inflammation^{151,177}. Further work to investigate the molecular mechanisms of xenophagy and their association with ageing and longevity is required.

3.5. Tissue-specific autophagy in ageing

As ageing is associated with a functional decline at both the tissue and organismal level, it is important to understand how ageing within individual tissues affects, and is affected by, ageing across the entire organism. Evidence from nematodes, flies, and mice has revealed that autophagy may have tissue-specific roles in regulating ageing¹⁴. Inhibition of Igg-1/Atg8 and atg-18 specifically in the body-wall muscle of adult worms, is sufficient to shorten the lifespan of both dietary-restricted eat-2 and insuln/IGF-1 receptor daf-2 long-lived mutants^{28,178}. In addition, the shortened lifespan of atg-18 mutants (ATG-18 is a member of the WIPI protein family, homologous to mammalian WIPI1 and WIPI2) can be suppressed by tissue-specific restoration of ATG-18 function: pan-neuronal- or intestine-specific expression of atq-18, fully restored the lifespan of atg-18 mutants to that of wild-type worms, while muscle- or hypodermis-specific rescue of ATG-18 had little to no ability to restore lifespan to wild-type levels¹⁷⁹. In flies, the promotion of autophagy in muscle tissue via overexpression of Atg8a or the transcription factor, FOXO, was sufficient to extend lifespan^{78,180}, while in mice, inhibition of autophagy through muscle-specific ATG7 deficiency, resulted in impaired muscle function (possibly via mitochondrial dysfunction) and lifespan decrease¹⁸¹. Furthermore, enhancing autophagy specifically in the intestine, maintains intestinal barrier function and promotes longevity and healthspan in worms and flies^{45,178}. Given that our tissues age unevenly, with some tissues presenting faster degeneration than others¹⁸², it will be interesting to determine how closely rates of ageing and autophagy are correlated in different tissues throughout life.

567

568

569

570571

572

573

574

575

576

577578

579580

581 582

583

584

585 586 587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603 604

605 606 607

608

609 610

611

612

613 614

615 616 617

618

619

620

621

4. Defective autophagy in diseases associated with accelerated ageing, neurodegenerative diseases and inflammaging

Accumulating evidence from studies using laboratory animals and human samples supports an essential role for autophagy in embryonic development, tissue health and lifespan through the suppression of age-associated inflammation (inflammaging), maintenance of genomic integrity, preservation of cellular/tissue homeostasis and rejuvenation of stem cells (Fig. 3a, references^{13,14,68,69}). While autophagy is tightly regulated by multiple molecular pathways involving central modulators of energy metabolism, such as AMPK, mTORC1, sirtuins, and calcineurin (Fig. 3b), several interventions such as dietary restriction, exercise, and supplementation of small chemical compounds (detailed below) stimulate autophagy⁶⁹. Recent preclinical studies link impaired general autophagy or subtypes of autophagy (in some cases, while a sub-type of selective autophagy may be impaired, there is no change, or even an increase, in general autophagy in some diseases) to pathological states, such as progeria and a series of accelerated ageing diseases⁶⁸ (Fig. 3c), neurodegenerative diseases^{19,37} (Fig. 3d), and other disorders 13,14,68,69. For example, the maintenance of CMA in aged cells sustains haematopoietic stem-cell function¹⁸³ and prevents collapse of the neuronal metastable proteome¹⁸⁴. Similarly, mitophagy, which is reduced in both normal ageing and in AD, extends healthspan¹⁴⁰ and suppresses Aβ- and pTau-induced memory loss when stimulated in aged tissues 138.

Understanding the relationship between compromised autophagy and other hallmarks of ageing will provide a better understanding of the molecular events that promote ageing and disease^{14,68,69}. Among the many age-related changes previously described, inflammation is linked to autophagy, as impaired autophagy drives inflammation, and has emerged as a major driver of age-related tissue damage. ^{63,69,185,186}. Inflammation is an evolutionary conserved protective mechanism designed to maintain organismal homeostasis against acute and local perturbations, and serves as an adaptive response to infection or injury ¹⁸⁷. Chronic, systemic inflammation develops progressively with age and contributes to organismal deterioration through a process termed "inflammaging" ¹⁸⁶.

Autophagy has been identified to be amongst the pivotal pillars that orchestrates the differentiation and metabolic state of innate immune cells. In particular, the balance between mTOR and AMPK activation plays a central role in immune cell maintenance and function. Upon mTOR activation, autophagic flux is reduced, accompanied by increased cellular glycolytic activity, giving rise to proliferative and pro-inflammatory phenotype of macrophages.

In contrast, AMPK activation drives autophagy and promotes the OXPHOS-dependent function of non- or anti-inflammatory macrophages¹⁸⁸.

Autophagy also regulates the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, which is an intracellular protein complex that activates caspase-1, which in turn catalyses the cleavage, activation, and subsequent release of pro-inflammatory cytokines (i.e., IL-1β) that can induce neurodegeneration^{186,189}. The NLRP3 inflammasome has been identified as a critical component of the innate immune response (i.e., microbial motifs, endogenous danger signals and environmental irritants) and orchestrates host immune homeostasis¹⁸⁹. Defective autophagy, for example in models of selective knockout or knockdown of genes/proteins involved in the autophagic core machinery (i.e., ATG5, ATG7, BECN1 and MAP1LC3B), results in unrestricted inflammasome activation and consequent inflammation. Likewise, promotion of autophagy through starvation or pharmaceuticals (i.e., rapamycin) inhibits the inflammasome¹⁹⁰. In addition, evidence stemming from an APP/PS1 mouse model of AD demonstrated mitophagy-induced inhibition of the NLRP3 inflammasome, thus reducing neuroinflammation¹³⁸. These findings imply an important role for autophagy in the regulation of inflammation, and in turn, ageing and neurodegenerative diseases.

5. Anti-ageing effects of autophagy modulators

 The mounting evidence that an imbalance of autophagy is an important age-associated characteristic has driven extensive research into the development of compounds that can promote autophagy¹. Pharmacological agents promoting autophagy can be classified based on their effect on the mTOR pathway¹⁹¹. mTOR inhibition by rapamycin has been shown to reduce protein synthesis and promote autophagy, both of which contribute to extended lifespan in yeast, nematodes, flies, and mice (**Table 2**). In addition, rapamycin has been demonstrated to protect against neurodegenerative diseases, including AD, via promotion of autophagy; however, rapamycin treatment was observed to be detrimental in the case of models of amyotrophic lateral sclerosis (ALS), possibly due to non-autophagy-related side effects¹⁹¹. Other pharmacological agents reported to promote autophagy via direct interaction with mTOR include Torin-1 and PP242¹⁹². The mTOR-independent promoters of autophagy mainly act via the AMPK pathway. Examples include metformin and trehalose, which have been demonstrated to be effective in enhancing autophagy, extending lifespan, and protecting against neurodegeneration in experimental models¹⁹¹.

Compounds such as resveratrol and spermidine modulate the acetylation state of proteins to regulate autophagy and promote longevity. Resveratrol is a natural polyphenol that reportedly promotes lifespan in C. elegans and healthspan in mice via activation of NAD+-dependent deacetylase, sirtuin-1 (SIRT1)^{112,193,194}. Spermidine is a polyamine that extends the lifespan of yeast, worms, flies and mice via enhancing autophagy through inhibition of EP300 (E1Abinding protein p300) acetyltransferase¹⁹⁵, among other mechanisms^{55,196-198}. The longevityextending effects of spermidine are abolished upon depletion or deletion of essential autophagy genes such as BECN1/ bec-1 in C. elegans and Atq7 in yeast and flies 197,199. Furthermore, pharmacological inhibition of XPO-1 results in enhanced autophagy (evidenced by an increase in the frequency of autophagosomes and autolysosomes) and increased lifespan in C. elegans. These effects were mediated by nuclear enrichment of HLH-30/TFEB, which occurred in an mTOR-independent manner⁴⁷. Additional modulators of TFEB that regulate autophagy, and which have also been demonstrated to protect against pathophysiological ageing, include ouabain and fisetin. Ouabain is a cardiac glycoside that enhances activation of TFEB through inhibition of the mTOR pathway and induces downstream autophagy-lysosomal gene expression and cellular restorative properties²⁰⁰. Ouabain has been shown to reduce the accumulation of abnormal toxic tau both in vitro and in vivo²⁰⁰. Fisetin is a flavonol, which was shown to facilitate the clearance of endogenous tau via TFEB (through inhibition of mTOR kinases) and Nrf2 activation²⁰.

Other small molecules that induce subtypes of autophagy, especially mitophagy, also enhance longevity and suppress age-associated diseases. These include NAD+, a fundamental metabolite in energy metabolism, redox homeostasis, mitochondrial function, or the arbitration of cell survival and death 185. NAD+-activated SIRTs stimulate autophagy via mTOR inhibition and deacetylation of several key autophagy proteins (ATG5, ATG7 and ATG8/LC3B) 201,202. In addition, the NAD+-SIRT axis activates mitophagy by increasing the activity of a series of mitophagy-related proteins, such as PINK1, Parkin, NIX (in *C. elegans* DCT-1) and BNIP3^{66,203}. Supplementation with NAD+ precursors, such as nicotinamide (NAM), nicotinamide riboside (NR), or nicotinamide mononucleotide (NMN), can increase lifespan and/or improve healthspan in worms, flies, and mice^{111,204-206}. NAD+ augmentation also prevents memory loss in both Aß and Tau C. elegans and mouse models of AD, in a mitophagy-dependent manner (requiring pink-1, pdr-1, or dct-1)¹³⁸. Over seven human clinical trials have shown the safety and bioavailability of NR (1 -2 g/day for up to 3 months); there have been more than 30 ongoing clinical trials on the use of NR to treat premature ageing and other age-related diseases (see review in¹⁸⁵). Another clinically promising mitophagy inducer is Urolithin A (UA), a metabolite of ellagitannins from the gut microflora. UA extends healthspan and lifespan in C. elegans, with lifespan extension depending on genes involved in autophagy (i.e., bec-1, sqst-1, vps-34) and mitophagy (pink-1, dct-1, and the non-specific Nrf2/skn-1)²⁰⁷. Intriguingly, UA inhibits memory loss in both Aβ and Tau C. elegans and mouse models of AD in a mitophagydependent manner (pink-1, pdr-1, or dct-1)¹³⁸. UA (500 mg and 1,000 mg /day for 4 weeks) was also shown to be safe in a stage I clinical trial²⁰⁸. A summary of different lifespan/healthbenefit mitophagy inducers can be found in Table 2. Encouraged by the clinical safety of NR and UA, their effects on healthspan and lifespan in the elderly deserve further investigation. Despite recent progress in the identification of novel as well as well-known autophagy-inducing compounds, it is also of great importance to highlight the pleiotropic effects of these pharmacological interventions and to completely understand the full complement of targets that they interact with in order to use them safely for therapeutic intervention.

While experimental/empirical evidence indicates that autophagy is defective in the elderly, it is conceivable that exposing individuals to autophagy inducers, dietary restriction, and exercise late in life could boost autophagy and result in benefits to tissue function ^{209,210} (**Fig. 4a**). Based on preclinical data, it is presumed that autophagy stimulation (ideally to increase autophagy to the levels observed early in adulthood) may be sufficient to provide benefits (**Fig. 4b**).

6. Conclusions and future perspectives

677

678

679

680 681

682

683 684

685

686

687

688 689

690

691 692

693

694 695

696

697 698

699

700

701

702

703

704 705

706

707 708

709

710 711 712

713

714

715

716

717 718

719

720

721

722 723

724

725

726

727

728

729 730

731

Mounting evidence from studies using laboratory animals, human tissues, and related clinical trials support that: a) there is an age-dependent decline of autophagy, b) autophagy is a crucial determinant of cellular health and organismal longevity and c) impairment/imbalance in autophagy promotes pathological ageing and disease. Given the broad spectrum of unique properties associated with autophagy, we propose 'compromised autophagy' is a central feature of normal ageing. Although the relationship between autophagy and ageing is often described as "decreased autophagy is detrimental" and "increased autophagy is beneficial". this may be too simplistic a picture. Instead, long-term health benefits will likely arise from achieving the right balance of autophagy, which itself will depend upon the tissue and organismal age. For example, in C. elegans, impairing autophagy early in life has a negative effect on longevity, whereas knock down of specific subset of autophagy genes in adulthood may have beneficial effects on lifespan⁵⁹. Similarly, increased autophagy through a hypermorphic allele of atg-5, has differential effects on polyglutamine aggregation in muscles and neurons of C. elegans²¹¹. In flies, a mild increase in autophagy extends lifespan, while strongly increasing autophagy shortens lifespan²¹². It should also be noted that autophagy induction may also result in unwanted effects, such as multiple senescent pathologies⁵⁹ and resistance to cancer therapy (reviewed in ²¹³). Collectively, these observations suggest that the level and balance among the different forms of autophagy in each tissue is highly specified for each stage of life and an understanding of this will be crucial for healthy ageing. Thus,

while different types of autophagy may influence ageing to different extents, a central goal for promoting health will be to find approaches that can fine-tune autophagy, to the right levels, at the right time, in the right tissues, to enhance health (**Fig. 4**). In order to achieve this, it will be critical to develop novel interventions that allow for the controlled delivery of autophagy modulators into specific tissues or cell types at precise stages of life. Such therapeutic strategies could then be administered chronically, acutely, or in a pulsed fashion as and when required. Additionally, it may be necessary to specifically induce either general or selective autophagy, in order to provide overall long-term health benefits⁶⁶. For example, the premature ageing diseases, such as A-T, XPA, and CS, exhibit increased general autophagy but impaired mitophagy; therefore, specifically stimulating mitophagy, rather than general autophagy, would be the most efficient way to counteract disease pathological features, while avoiding detrimental side-effects⁶⁶.

 To this end, there remain many outstanding questions related to autophagy in ageing that need to be addressed. What are the intricate mechanisms that orchestrate distinct autophagic pathways? How is autophagy spatially- and temporally-regulated and how does the disruption of this regulation suppress or promote disease? Are some aspects of autophagy more important in an age- and/or tissue-dependent manner? What are the determining factors that dictate the route of degradation via the UPS or autophagy? How are clearance mechanisms balanced with synthesis and folding through the proteostasis network? What are the thresholds of life-benefit and life-detrimental autophagy? In line with the traditional Chinese 'Yin-Yang' philosophy, autophagy must be balanced, as diminished autophagy results in the accumulation of toxic subcellular components while excessive autophagy can lead to organ atrophy and other side effects^{14,37,59,69,212}. Furthermore, compensatory responses between proteolytic systems (e.g., between autophagy and the UPS²¹⁴) play a critical role in determining the onset and rate of age-related tissue deterioration, and should be considered in future experimental design and data interpretation. Finally, are there any conditions or diseases where we should be cautious about inducing autophagy in that protection against one form of pathology increases the risk for another? E.g., pancreatic cancer cells may hijack autophagy processes to obtain nutrients for growth; hence, in this condition autophagy inhibition in combination with cancer chemotherapies may inhibit pancreatic cancer growth^{215,216}. Addressing these questions will facilitate our understanding of the ageing process and, more importantly, enable us to identify novel targets that may be manipulated for therapeutic intervention in ageassociated diseases.

Acknowledgements

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782 783

784

785

786

787

788

789

790

791

792

793

794

795 796 797

798

799

800

801

802

803

E.F.F. was supported by HELSE SØR-ØST (#2017056, #2020001, #2021021), the Research Council of Norway (#262175 and #277813), the National Natural Science Foundation of China (#81971327), Akershus University Hospital (#269901, #261973), the Civitan Norges Forskningsfond for Alzheimers sykdom (for a 3-year Ph.D. fellowship, #281931), the Czech Republic-Norway KAPPA programme (with Martin Vyhnálek, #TO01000215), and the Rosa sløyfe/Norwegian Cancer Society & Norwegian Breast Cancer Society (#207819). J.L. is supported by a BBSRC David Phillips Fellowship, a BBSRC Responsive Mode Grant, an AMS Springboard Award and a Wellcome Trust ISSF award, AKS is supported by a Wellcome Trust investigator Award 103830/Z/14/Z. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.' AS is supported by the Norwegian Cancer Society (#171318), the Research Council of Norway (#221831 and through its Centres of Excellence funding scheme (#262652)), as well as HELSE SØR-ØST (#2020032). TJ is supported by the by the Norwegian Cancer Society (#190214) and the Research Council of Norway (#249884). NT was supported by grants from the European Research Council (ERC GA695190, MANNA; ERC-GA737599, NeuronAgeScreen). M.H. is supported by the National Institute of Health (AG038664 and GM117466) as well as the American Federation for Aging Research and the Larry L. Hillblom Foundation. D.C.R. is supported by the UK Dementia Research Institute (funded by the MRC, Alzheimer's Research UK and the Alzheimer's Society) (UKDRI-2002 to DCR), The Tau Consortium, Alzheimer's Research UK, an anonymous donation to the Cambridge Centre for Parkinson-Plus, and The Roger de Spoelberch Prize. I.B. is supported by funding from the European Research Council (ERC PoC 842174), the Cancer Research UK City of London Centre Award [C7893/A28990]. L.P. is supported by a Wellcome Trust Collaborative Award. the Max Planck Society and the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) / ERC grant agreement number 268739. The figures were generated using BioRender via subscription.

Declaration of Interests

E.F.F. has CRADA arrangement with ChromaDex, and is consultant to Aladdin Healthcare Technologies, Vancouver Dementia Prevention Centre, and Intellectual Labs. AKS is a consultant to Oxford Healthspan. D.C.R. is a consultant for Aladdin Healthcare Technologies Ltd, Drishti Discoveries and Nido Biosciences. All other authors declare no competing interests.

Figure Legends

804

805 806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832 833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

Figure 1. Different mechanisms of autophagy. (a) Macroautophagy: The non-selective process of macroautophagy will target macromolecules or sub-cellular organelles in bulk. Cytoplasmic material is sequestered into an autophagosome and delivered to the lysosome (or endo-lysosome) for degradation (I). Selective macroautophagy involves recognition of specific cytoplasmic cargo via autophagy receptors that also interact with LC3 in the autophagic membrane, leading to cargo sequestration into autophagosomes that are delivered to a lysosome (or endo-lysosome) for degradation. This includes II) Aggrephagy: aggregated proteins are ubiquitinated and targeted by ubiquitin-binding autophagy receptors such as p62 (or NBR1). III) Glycophagy: STBD1 (Genethonin-1) binds to glycogen and GABARAP, facilitating lysosomal glycogen break down into non-phosphorylated glucose by enzymes like glycogen-hydrolyzing acid α-glucosidase (GAA). **IV) Lipophagy**: the unknown receptor/s (yellow) involved in sequestration of lipid droplets is yet to be determined. Lysosomal lipids are degraded into free fatty acids, which are then converted into ATP. V) Granulophagy: sequestration of stress granules (RNA + proteins) is mediated by Cdc48/VCP, allowing the stress granule to be delivered to the lysosome for degradation. VI) Mitophagy: Damaged mitochondria can be fully engulfed by mitophagy (left). Soluble or membrane-bound mitophagy receptors can bind to the mitochondrion as well as to LC3, leading to engulfment of the mitochondrion into an autophagosome and subsequent delivery to a lysosome for degradation. Piecemeal mitophagy (right) allows degradation of parts of the mitochondria via binding of MTX1 to LC3C, resulting in the recruitment of p62 and autophagosome formation. VII) ERphagy: In mammals it uses the specific receptors FAM134B, RTN3L, ATL3, SEC62, CCPG1 & TEX264, which are located in different parts of the ER. These receptors bind to LC3, leading to sequestration of ER into an autophagosome and lysosomal degradation of the ER. VIII) Nucleophagy: In mammals, when nucleophagy is triggered, nuclear LC3 binds to lamin B1. These form a bulge which is pinched off to the cytoplasm where degradation by autophagy will occur. IX) Xenophagy A: A bacterium's DNA is detected by c-GAS, sensors which trigger a process of ubiquitination via Smurf1. This is followed by the attachment of NBR1 to the ubiquitin chains. The receptor NBR1 binds to LC3 in order to continue with the autophagy process for the degradation of the bacterium. X) Xenophagy B: A bacterium damages the membrane of the phagosome, exposing interior glycans. These glycans recruit Galectin-8 (Gal-8). NDP52 recognizes Gal-8 and then recruits TBK1, LC3C, Nap and Sintbad. Receptors optineurin, p62 and NDP52 interact with the ubiquitin on the pathogen and recruit the autophagic engulfment system, the engulfed pathogen is then brought for degradation. XI) Lysophagy: occurs upon lysosomal membrane permeabilization and can be achieved with or without ubiquitination. Recruitment of Galectin-3 (Gal-3) to damaged lysosomes further recruits TRIM16 and autophagic proteins like ULK1 and ATG16L1. Furthermore, ubiquitination on the lysosome results in the recruitment of p62 that binds to LC3 to facilitate the autophagic process. In a parallel ubiquitin-independent process, Gal-8 is recruited to damaged lysosomes, which is capable of directly binding to the receptor NDP52 that interacts with LC3 to continue the autophagic process. b) Microautophagy: involves capture of cytoplasmic components through a direct invagination of endo-lysosome membranes and can be XII) non-specific (bulk) or highly specific. Examples of selective microautophagy in mammalian cells include XIII) Micro-ER-phagy: which uses the receptor SEC62 and involves ER capture and degradation by invagination of the lysosome/endolysosome and XIV) endosomal microautophagy of proteins having the pentapeptide motif KFERQ in a process requiring the chaperone HSC70. (c) Chaperone-mediated autophagy (CMA): also involves XV) targeting of proteins containing a KFERQ pentapeptide related motif by HSC70 and other cochaperones such as HSP40. Then, the substrate is imported into lysosomes through the receptor LAMP2A, for further degradation. The LAMP2A receptor is modulated by the glial fibrillary acidic protein (GFAP). Finally, in a CMA-like manner, XVI) DN/RNAutophagy can occur: nucleic acids (DNA/RNA) bind to the receptor LAMP2C (orange) which also binds to lysosomes. This process allows nucleic acids to be taken up by the lysosomes. It has been

proposed that a transporter called SIDT2 (green) might play a role in direct uptake of nucleic acids by the lysosomes as well.

Figure 2. Core machinery of Autophagy. The initiation of autophagy requires the ULK1 kinase complex, which is tightly regulated by AMPK and mTOR, acting as an activator and inhibitor, respectively. AMPK activates ULK1 through phosphorylation. The ULK1 complex, composed of FIP200, ATG13 and ATG101, stimulates the class III phosphatidylinositol 3kinase complex (PIK3C3 complex), which includes BECN1 (which can be inhibited by BCL2), AMBRA1, ATG14L, VPS15 and VPS34. This complex then produces a pool of PtdIns3P, which leads to the recruitment of WIPI proteins, which will recover ATG-9 vesicles from previous membranes, as well as recruiting ATG5-ATG12-ATG16L1 (E3). LC3 is first cleaved by an ATG4 protease to form cytosolic LC3-I, which is further recognized by E1 (ATG7), E2 (ATG3) and E3 leading to its conjugation to phosphatidylethanolamine (PE). After this process, LC3-I is referred as LC3-II. LC3-II binds to LIR-containing autophagy receptors (AR, such as p62) bound to cargos targeted for degradation. Fusion of autophagosomes with lysosomes is mainly mediated by the assistance of Rab proteins, SNARE proteins and a HOPS complex. After fusion, cargo is degraded by lysosomal hydrolases and the degraded products can be reused by the cell. LC3-II bound to the outer membrane is cleaved by ATG4 to be reused for a new round of lipidation.

Figure 3. Autophagy in health and disease. (a) Autophagy participates in multiple processes that are essential for longevity. (b) A brief summary of some of the major known mechanisms that regulate autophagy in multiple organisms, and their influences in the process. (c) A list summarizing premature ageing diseases with impaired mitophagy as a cause of mitochondrial dysfunction, which contributes to short lifespan (LS) and healthspan (HS). These premature ageing diseases are Ataxia Telangiectasia (AT), Cockayne Syndrome (CS), Fanconi Anemia (FA), Hutchinson-Gilford Syndrome (HG), Werner Syndrome (WS), Xeroderma Pigmentosum (XP, especially group A). Changes of autophagy and mitophagy in HG are elusive. (d) Autophagy (including sub-types of selective autophagy, like mitophagy) is impaired in broad neurodegenerative diseases, where it may drive or exacerbate disease progression. Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). We emphasize that these are not the only drivers of the disease and other processes may play roles leading the pathology and symptomatology. '?', information unknown.

Figure 4. Maintaining autophagy through lifestyle and medical interventions prolongevity. (a) Potential interventions to stimulate autophagy: autophagy inducers, dietary restriction, exercise, and genetic approaches. (b) Autophagy induction could positively impact human health.

Table 1. A summary of autophagy genes/proteins that can be pro-longevity.

Protein	Functions	Modification effect in longevity
(names in		
different species)		
Y: ATG1 W: UNC-51 F: Atg1 M: ULK1 H: ULK1	Kinase required for the formation of the autophagosome ²¹⁷ .	 (W) mutations in the gene (whole life) cause the organism to age faster³⁹. (F, Y, W) Essential for longevity when using approaches such as mTOR suppression, ↑AMPK, dietary restriction, rapamycin and others^{39,45,218,219}.
Y: ATG2 W: ATG-2 F: Atg2 M: ATG2A and ATG2B H: ATG2A and ATG2B	Lipid transport protein crucial for the formation of the autophagosome ²²⁰ .	(F) Knockdown reduces lifespan ²²¹ . The levels significantly decrease with age ³⁰ .
Y: ATG4 W: ATG-4.1 and ATG-4.2 F: Atg4b M: ATG4A to ATG4D H: ATG4A to ATG4D	Protease required for conjugation/deconjugation of Atg8 proteins to phosphatidylethanolamine ²²² .	(W) essential for longevity when using approaches such as mir-34 loss-of-function ²²³ .
Y: ATG5 W: ATG-5 F: Atg5 M: ATG5 H: ATG5	Part of the E3 complex required for Atg8 lipidation ²²⁴ .	(M) Ubiquitous ↑ in transgenic mice increase lifespan ⁴⁴ . (F, Y) gene is essential for longevity induced by methionine restriction and rapamycin ^{225,226} .
Y: Vps30/Atg6 W: BEC-1 F: Atg6 M: BECN1(Beclin-1) H: BECN1 (Beclin-1)	Subunit of the class III PI3K complex required for autophagosome formation ²²⁴ .	(F, W, Y) mutations in the gene (whole life) cause the organism to age faster. Essential for longevity when using approaches such as mTOR suppression, <i>mir-34</i> loss-of-function, treatment by spermidine and urolithin A, and dietary restriction ^{39,61,199,207,223,227} .
Y: ATG7 W: ATG-7 F: Atg7 M: Atg7 H: ATG7	E1 enzyme required for Atg8 lipidation ²²⁴ .	(M, W) absence of the gene decreases lifespan, increases atrophy and inflammation ^{181,228} . (F, W, Y) important for longevity when using approaches, such as spermidine, dietary restriction and methionine restriction ^{199,225,227} . (H) significantly reduced in the muscle of sarcopenic adults ¹⁸¹ . (M) significantly reduced in the muscles of older mice ¹⁸¹ .
Y: ATG8 W: LGG-1 and LGG-2 F: Atg8a M: LC3/GABARAP H: LC3/GABARAP	Small ubiquitin protein conjugated to PE in autophagic membranes. Interacts with protein containing AIM/LIR motifs.	 (F) ↑ in neurons increases lifespan³⁰. (F) ↑ in muscles increases lifespan¹⁸⁰. (F) mutations in the gene produce neurodegeneration and reduces lifespan³⁰. (Y) essential for longevity when using approaches such as methionine restriction²²⁵. (F) Crucial for the formation of the autophagosome. At week 4, it is downregulated up to 60%³⁰
Y: ATG9 W: ATG-9 F: Atg9 M: ATG9A H: ATG9A	Transmembrane protein required for autophagosome formation ²²⁹ .	(W) essential for longevity when using approaches such as mir-34 loss-of-function ²²³ .
Y: ATG12 W: LGG-3 F: Atg12 M: ATG12 H: ATG12	Forms a complex with ATG5 and ATG16L1 (W: ATG-16.1 & H/M: ATG16L1) ²³⁰ .	(W) ↓ from egg lay (RNAi) reduces lifespan ²²⁸ .
Y: ATG15 W: ? F: ? M: ? H: ?	Required for the lysis of subvacuolar vesicles ²³¹ .	(Y) essential for longevity when using approaches such as dietary restriction ²³² .
Y: ATG18 W: ATG-18 F: Atg18 M: WIPI-1/2 H: WIPI-1/2	PtdIns3P binding proteins essential for autophagy ²³³ .	(W) mutations in the gene (whole life) cause the organism to age faster and loss of function reduces lifespan ^{28,39} . Its expression in the neurons and intestine is essential for maintaining wild type lifespan ¹⁷⁹ . ↓ S6K increases its levels ²³⁴ . Essential for longevity when using approaches such as mTOR suppression and

		dietary restriction ^{39,179} . (F) Significantly decreases with age ³⁰ .
Y: ? W: PDR-1 F: Parkin M: Parkin H: PRKN	Ubiquitin E3 ligase that ubiquitinates outer mitochondrial membrane (OMM) proteins, promoting mitophagy ²³⁵ .	(F) ↑ ubiquitously or in neurons (during ageing) increases lifespan ²³⁶ .
Y: ? W: PINK-1 F: Pink1 M: PINK1 H: PINK1	Mitochondrial kinase that phosphorylates ubiquitin and recruits Parkin upon mitochondria depolarization ²³⁷ .	(W) essential for longevity when using multiple approaches, such as nicotinamide riboside and urolithin A treatment among others ^{140,207,238} .
Y:? W: SQST-1 F: ref(2)P M: p62 and NBR1 H: P62/SQSTM1 and NBR1 (many other receptors exist)	Ubiquitin-binding autophagy receptor involved in selective autophagy ²³⁹ .	(W) Strains that ↑ the gene have increased lifespan ^{76,77} . Essential for longevity and for mitophagy inducers (e.g., urolithin A)-induced lifespan/healthspan improvement ^{76,207,238} .
Y: ? W: HLH-30 F: ? M: TFEB H: TFEB HLH-30 (W), MITF (F), TFEB (M & H)	Transcription factor for genes involved in autophagy, lysosome, and phagocytosis ⁴³ .	(W) Strains that have ↑ have increased lifespan ⁴³ .
Y: VPS34 W: VPS-34 F: Pi3K59F M: VPS34 H: PIK3C3	PI3K required for autophagosome formation ²⁴⁰ .	(W) essential for longevity when using multiple approaches, such as urolithin A treatment and dietary restrictions ^{61,207} .

Abbreviations: Yeast (Y), Worms (W), Flies (F), Mice (M), Humans (H), ↑ (Overexpression), ↓ (Reduced expression)

Table 2. Summary of autophagy inducers which extend healthspan and increase lifespan in laboratory animals

Pharmacological Agents	Health benefits	Modes of action
Metformin (W, M), ↑ lifespan, healthspan		activates AMPK and other mechanisms ²⁴¹ (also reviewed in ²⁴²)
Rapamycin	(W, F, M), ↑ lifespan, different healthspan parameters	Direct autophagy induction via mTOR inhibition (reviewed in ²⁴²)
Resveratrol	(Y, W, F, M¹) ↑ lifespan, different healthspan parameters	SIRT1-dependent induction of autophagy, and non-autophagy pathways ¹¹² (reviewed in ⁶⁸)
Spermidine	(W, F, M, R), ↑ median lifespan, different healthspan parameters	Autophagy, anti-inflammation, arginine and NO metabolism ^{196,199}
NR/NMN	(W, F, M) ↑ lifespan, (W, F, M) healthspan, (M) memory	Autophagy/mitophagy-dependent and also- independent pathways (reviewed in ^{185,243})
Urolithin A	(W) ↑ lifespan, healthspan, (W, M) memory	Autophagy/mitophagy induction ^{138,207,208}
Actinonin (W, M) ↑ memory		Autophagy/mitophagy-dependent pathway ¹³⁸

Tomatidine	(W) ↑ lifespan, healthspan	Mitophagy induction via the SKN-1/Nrf2 pathway ¹⁴²
Trehalose	(W) ↑ lifespan, healthspan ²⁴⁴	?
myo-inositol (MI)	(W) ↑ lifespan, healthspan	PINK1-dependent mitophagy induction ²⁴⁵
XPO1 inhibitors	(W, F) ↑ lifespan, improved conditions in neurodegenerative models	Induction of nuclear localization of HLH- 30/TFEB ⁴⁷

909	
910	

 Abbreviations: Yeast (Y), Worms (W), Flies (F), Mice (M), Humans (H), Rat (R), \uparrow (Overexpression), \downarrow (Reduced expression), NR (nicotinamide riboside), NMN (nicotinamide mononucleotide),

¹No extension in WT mice with normal diet, but extended lifespan in the high-fat diet fed mice¹¹².

References

917

- 918 1 Leidal, A. M., Levine, B. & Debnath, J. Autophagy and the cell biology of age-related disease. 919 *Nat Cell Biol* **20**, 1338-1348, doi:10.1038/s41556-018-0235-8 (2018).
- 920 2 Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global challenges of ageing. *Nature* 921 **561**, 45-56, doi:10.1038/s41586-018-0457-8 (2018).
- 922 3 Fang, E. F. *et al.* A research agenda for ageing in China in the 21st century (2nd edition):
- Focusing on basic and translational research, long-term care, policy and social networks.

 Ageing Res Rev 64, 101174, doi:10.1016/j.arr.2020.101174 (2020).
- 925 4 Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev* 926 *Mol Cell Biol* **19**, 349-364, doi:10.1038/s41580-018-0003-4 (2018).
- 927 5 Ashford, T. P. & Porter, K. R. Cytoplasmic components in hepatic cell lysosomes. *J Cell Biol* **12**, 928 198-202, doi:10.1083/jcb.12.1.198 (1962).
- 929 6 Deter, R. L. & De Duve, C. Influence of glucagon, an inducer of cellular autophagy, on some 930 physical properties of rat liver lysosomes. *J Cell Biol* **33**, 437-449, doi:10.1083/jcb.33.2.437 931 (1967).
- 932 7 Klionsky, D. J. Autophagy revisited: a conversation with Christian de Duve. *Autophagy* **4**, 740-933 743, doi:10.4161/auto.6398 (2008).
- Tsukada, M. & Ohsumi, Y. Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. *FEBS Lett* **333**, 169-174, doi:10.1016/0014-5793(93)80398-e (1993).
- 937 9 Harding, T. M., Morano, K. A., Scott, S. V. & Klionsky, D. J. Isolation and characterization of yeast mutants in the cytoplasm to vacuole protein targeting pathway. *J Cell Biol* **131**, 591-602, doi:10.1083/jcb.131.3.591 (1995).
- 940 10 Thumm, M. *et al.* Isolation of autophagocytosis mutants of Saccharomyces cerevisiae. *FEBS* 941 *Lett* **349**, 275-280, doi:10.1016/0014-5793(94)00672-5 (1994).
- 942 11 Schlumpberger, M. *et al.* AUT1, a gene essential for autophagocytosis in the yeast Saccharomyces cerevisiae. *J Bacteriol* **179**, 1068-1076, doi:10.1128/jb.179.4.1068-1076.1997 (1997).
- 945 12 Straub, M., Bredschneider, M. & Thumm, M. AUT3, a serine/threonine kinase gene, is 946 essential for autophagocytosis in Saccharomyces cerevisiae. *J Bacteriol* **179**, 3875-3883, 947 doi:10.1128/jb.179.12.3875-3883.1997 (1997).
- 948 13 Kaushik, S. & Cuervo, A. M. The coming of age of chaperone-mediated autophagy. *Nat Rev* 949 *Mol Cell Biol* **19**, 365-381, doi:10.1038/s41580-018-0001-6 (2018).
- Hansen, M., Rubinsztein, D. C. & Walker, D. W. Autophagy as a promoter of longevity:
 insights from model organisms. *Nat Rev Mol Cell Biol* 19, 579-593, doi:10.1038/s41580-018-0033-y (2018).
- 953 15 Bjorkoy, G. *et al.* p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J Cell Biol* **171**, 603-614, 955 doi:10.1083/jcb.200507002 (2005).
- Pankiv, S. *et al.* p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J Biol Chem* **282**, 24131-24145, doi:10.1074/jbc.M702824200 (2007).
- 959 17 Kirkin, V. History of the Selective Autophagy Research: How Did It Begin and Where Does It Stand Today? *J Mol Biol* **432**, 3-27, doi:10.1016/j.jmb.2019.05.010 (2020).
- Gatica, D., Lahiri, V. & Klionsky, D. J. Cargo recognition and degradation by selective autophagy. *Nat Cell Biol* **20**, 233-242, doi:10.1038/s41556-018-0037-z (2018).
- 963 19 Menzies, F. M., Fleming, A. & Rubinsztein, D. C. Compromised autophagy and neurodegenerative diseases. *Nat Rev Neurosci* **16**, 345-357, doi:10.1038/nrn3961 (2015).
- 965 20 Kim, S. *et al.* Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors. *Sci Rep* **6**, 24933, doi:10.1038/srep24933 967 (2016).

- 968 21 Medina, D. L. *et al.* Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. *Nat Cell Biol* **17**, 288-299, doi:10.1038/ncb3114 (2015).
- 970 22 Settembre, C. *et al.* A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. *EMBO J* **31**, 1095-1108, doi:10.1038/emboj.2012.32 (2012).
- 972 23 El-Houjeiri, L. *et al.* The Transcription Factors TFEB and TFE3 Link the FLCN-AMPK Signaling 973 Axis to Innate Immune Response and Pathogen Resistance. *Cell Rep* **26**, 3613-3628 e3616, 974 doi:10.1016/j.celrep.2019.02.102 (2019).
- 975 24 Cuervo, A. M. & Dice, J. F. How do intracellular proteolytic systems change with age? *Front Biosci* **3**, d25-43, doi:10.2741/a264 (1998).
- 977 25 Sun, Y. *et al.* Lysosome activity is modulated by multiple longevity pathways and is important for lifespan extension in C. elegans. *Elife* **9**, doi:10.7554/eLife.55745 (2020).
- Sarkis, G. J., Ashcom, J. D., Hawdon, J. M. & Jacobson, L. A. Decline in protease activities with age in the nematode Caenorhabditis elegans. *Mech Ageing Dev* **45**, 191-201, doi:10.1016/0047-6374(88)90001-2 (1988).
- Hughes, A. L. & Gottschling, D. E. An early age increase in vacuolar pH limits mitochondrial function and lifespan in yeast. *Nature* **492**, 261-265, doi:10.1038/nature11654 (2012).
- Chang, J. T., Kumsta, C., Hellman, A. B., Adams, L. M. & Hansen, M. Spatiotemporal regulation of autophagy during Caenorhabditis elegans aging. *Elife* **6**, doi:10.7554/eLife.18459 (2017).
- 986 29 Wilhelm, T. *et al.* Neuronal inhibition of the autophagy nucleation complex extends life span in post-reproductive C. elegans. *Genes Dev* **31**, 1561-1572, doi:10.1101/gad.301648.117 988 (2017).
- 989 30 Simonsen, A. *et al.* Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult Drosophila. *Autophagy* **4**, 176-184, 991 doi:10.4161/auto.5269 (2008).
- 992 31 Kaushik, S. *et al.* Loss of autophagy in hypothalamic POMC neurons impairs lipolysis. *EMBO* 993 *Rep* **13**, 258-265, doi:10.1038/embor.2011.260 (2012).
- 994 32 Ott, C., Konig, J., Hohn, A., Jung, T. & Grune, T. Macroautophagy is impaired in old murine 995 brain tissue as well as in senescent human fibroblasts. *Redox Biol* **10**, 266-273, 996 doi:10.1016/j.redox.2016.10.015 (2016).
- 997 33 Triplett, J. C. *et al.* Age-related changes in the proteostasis network in the brain of the naked 998 mole-rat: Implications promoting healthy longevity. *Biochim Biophys Acta* **1852**, 2213-2224, 999 doi:10.1016/j.bbadis.2015.08.002 (2015).
- 1000 34 Yu, Y. *et al.* The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits. *Behav Brain Res* **334**, 155-162, doi:10.1016/j.bbr.2017.07.003 (2017).
- Lipinski, M. M. et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci U S A 107, 14164-14169, doi:10.1073/pnas.1009485107 (2010).
- 1006 36 Cheon, S. Y., Kim, H., Rubinsztein, D. C. & Lee, J. E. Autophagy, Cellular Aging and Age-related Human Diseases. *Exp Neurobiol* **28**, 643-657, doi:10.5607/en.2019.28.6.643 (2019).
- 1008 37 Lou, G. *et al.* Mitophagy and Neuroprotection. *Trends Mol Med,* doi:10.1016/j.molmed.2019.07.002 (2019).
- 1010 38 Matecic, M. *et al.* A microarray-based genetic screen for yeast chronological aging factors. 1011 *PLoS Genet* **6**, e1000921, doi:10.1371/journal.pgen.1000921 (2010).
- Toth, M. L. *et al.* Longevity pathways converge on autophagy genes to regulate life span in Caenorhabditis elegans. *Autophagy* **4**, 330-338, doi:10.4161/auto.5618 (2008).
- 1014 40 Kuma, A., Komatsu, M. & Mizushima, N. Autophagy-monitoring and autophagy-deficient mice. *Autophagy* **13**, 1619-1628, doi:10.1080/15548627.2017.1343770 (2017).
- 1016 41 Lin, X. X. *et al.* DAF-16/FOXO and HLH-30/TFEB function as combinatorial transcription factors to promote stress resistance and longevity. *Nat Commun* **9**, 4400,
- 1018 doi:10.1038/s41467-018-06624-0 (2018).

- Melendez, A. *et al.* Autophagy genes are essential for dauer development and life-span extension in C. elegans. *Science* **301**, 1387-1391, doi:10.1126/science.1087782 (2003).
- Lapierre, L. R. *et al.* The TFEB orthologue HLH-30 regulates autophagy and modulates longevity in Caenorhabditis elegans. *Nat Commun* **4**, 2267, doi:10.1038/ncomms3267 (2013).
- 1023 44 Pyo, J. O. *et al.* Overexpression of Atg5 in mice activates autophagy and extends lifespan. *Nat Commun* **4**, 2300, doi:10.1038/ncomms3300 (2013).
- Ulgherait, M., Rana, A., Rera, M., Graniel, J. & Walker, D. W. AMPK modulates tissue and organismal aging in a non-cell-autonomous manner. *Cell Rep* **8**, 1767-1780, doi:10.1016/j.celrep.2014.08.006 (2014).
- 1028 46 Fernandez, A. F. *et al.* Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. *Nature* **558**, 136-140, doi:10.1038/s41586-018-0162-7 (2018).
- Silvestrini, M. J. *et al.* Nuclear Export Inhibition Enhances HLH-30/TFEB Activity, Autophagy, and Lifespan. *Cell Rep* **23**, 1915-1921, doi:10.1016/j.celrep.2018.04.063 (2018).
- Harrison, D. E. *et al.* Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* **460**, 392-395, doi:10.1038/nature08221 (2009).
- 1034 49 Pareja-Cajiao, M. *et al.* Age-related impairment of autophagy in cervical motor neurons. *Exp* Gerontol **144**, 111193, doi:10.1016/j.exger.2020.111193 (2021).
- Nettesheim, A. *et al.* Autophagy in the Aging and Experimental Ocular Hypertensive Mouse Model. *Invest Ophthalmol Vis Sci* **61**, 31, doi:10.1167/iovs.61.10.31 (2020).
- 1038 51 Fernando, R. *et al.* Age-Related Maintenance of the Autophagy-Lysosomal System Is Dependent on Skeletal Muscle Type. *Oxid Med Cell Longev* **2020**, 4908162, doi:10.1155/2020/4908162 (2020).
- Liang, W. *et al.* Aging is associated with a decline in Atg9b-mediated autophagosome formation and appearance of enlarged mitochondria in the heart. *Aging Cell* **19**, e13187, doi:10.1111/acel.13187 (2020).
- Kamihara, T. & Murohara, T. Bioinformatics analysis of autophagy-lysosomal degradation in cardiac aging. *Geriatr Gerontol Int* **21**, 108-115, doi:10.1111/ggi.14098 (2021).
- Fang, Y. *et al.* Autophagy-Sirt3 axis decelerates hematopoietic aging. *Aging Cell* **19**, e13232, doi:10.1111/acel.13232 (2020).
- Alsaleh, G. *et al.* Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses. *Elife* **9**, doi:10.7554/eLife.57950 (2020).
- De Risi, M. *et al.* Mechanisms by which autophagy regulates memory capacity in ageing. Aging Cell **19**, e13189, doi:10.1111/acel.13189 (2020).
- Yamamuro, T. *et al.* Age-dependent loss of adipose Rubicon promotes metabolic disorders via excess autophagy. *Nat Commun* **11**, 4150, doi:10.1038/s41467-020-17985-w (2020).
- Thou, B. *et al.* Mitochondrial Permeability Uncouples Elevated Autophagy and Lifespan Extension. *Cell* **177**, 299-314 e216, doi:10.1016/j.cell.2019.02.013 (2019).
- 1056 59 Ezcurra, M. *et al.* C. elegans Eats Its Own Intestine to Make Yolk Leading to Multiple Senescent Pathologies. *Curr Biol* **28**, 2544-2556 e2545, doi:10.1016/j.cub.2018.06.035 (2018).
- 1059 60 Lapierre, L. R. *et al.* Autophagy genes are required for normal lipid levels in C. elegans. 1060 *Autophagy* **9**, 278-286, doi:10.4161/auto.22930 (2013).
- Hansen, M. *et al.* A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. *PLoS Genet* **4**, e24, doi:10.1371/journal.pgen.0040024 (2008).
- Labbadia, J. & Morimoto, R. I. The biology of proteostasis in aging and disease. *Annu Rev* Biochem **84**, 435-464, doi:10.1146/annurev-biochem-060614-033955 (2015).
- 1065 63 Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. 1066 *Cell* **153**, 1194-1217, doi:10.1016/j.cell.2013.05.039 (2013).
- Ravikumar, B., Duden, R. & Rubinsztein, D. C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum Mol Genet* **11**, 1107-1117, doi:10.1093/hmg/11.9.1107 (2002).

1070	65	Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of
1071		polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36,
1072		585-595, doi:10.1038/ng1362 (2004).

- 1073 66 Fang, E. F. *et al.* Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 1074 reduction. *Cell* **157**, 882-896, doi:10.1016/j.cell.2014.03.026 (2014).
- Boland, B. *et al.* Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. *Nat Rev Drug Discov* **17**, 660-688, doi:10.1038/nrd.2018.109 (2018).
- 1077 68 Fang, E. F. *et al.* Nuclear DNA damage signalling to mitochondria in ageing. *Nat Rev Mol Cell Biol* **17**, 308-321, doi:10.1038/nrm.2016.14 (2016).
- 1079 69 Rubinsztein, D. C., Marino, G. & Kroemer, G. Autophagy and aging. *Cell* **146**, 682-695, doi:10.1016/j.cell.2011.07.030 (2011).
- 1081 70 Kumsta, C., Chang, J. T., Schmalz, J. & Hansen, M. Hormetic heat stress and HSF-1 induce autophagy to improve survival and proteostasis in C. elegans. *Nat Commun* **8**, 14337, doi:10.1038/ncomms14337 (2017).
- Juhasz, G., Erdi, B., Sass, M. & Neufeld, T. P. Atg7-dependent autophagy promotes neuronal health, stress tolerance, and longevity but is dispensable for metamorphosis in Drosophila.

 Genes Dev 21, 3061-3066, doi:10.1101/gad.1600707 (2007).
- Hara, T. *et al.* Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* **441**, 885-889, doi:10.1038/nature04724 (2006).
- 1089 73 Komatsu, M. *et al.* Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* **441**, 880-884, doi:10.1038/nature04723 (2006).
- Friedman, L. G. *et al.* Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain. *J Neurosci* **32**, 7585-7593, doi:10.1523/JNEUROSCI.5809-11.2012 (2012).
- Schneider, J. L. *et al.* Loss of hepatic chaperone-mediated autophagy accelerates proteostasis failure in aging. *Aging Cell* **14**, 249-264, doi:10.1111/acel.12310 (2015).
- 1096 76 Kumsta, C. *et al.* The autophagy receptor p62/SQST-1 promotes proteostasis and longevity in C. elegans by inducing autophagy. *Nat Commun* **10**, 5648, doi:10.1038/s41467-019-13540-4 (2019).
- 1099 77 Aparicio, R., Rana, A. & Walker, D. W. Upregulation of the Autophagy Adaptor p62/SQSTM1 1100 Prolongs Health and Lifespan in Middle-Aged Drosophila. *Cell Rep* **28**, 1029-1040 e1025, doi:10.1016/j.celrep.2019.06.070 (2019).
- Demontis, F. & Perrimon, N. FOXO/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging. *Cell* **143**, 813-825, doi:10.1016/j.cell.2010.10.007 (2010).
- Nezis, I. P. *et al.* Ref(2)P, the Drosophila melanogaster homologue of mammalian p62, is required for the formation of protein aggregates in adult brain. *J Cell Biol* **180**, 1065-1071, doi:10.1083/jcb.200711108 (2008).
- Lopez, A. *et al.* A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. *Brain* **140**, 1128-1146, doi:10.1093/brain/awx005 (2017).
- Rocchi, A. *et al.* A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease. *PLoS Genet* **13**, e1006962, doi:10.1371/journal.pgen.1006962 (2017).
- Fu, H. *et al.* A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. *Nat Neurosci* **22**, 47-56, doi:10.1038/s41593-018-0298-7 (2019).
- Schinaman, J. M., Rana, A., Ja, W. W., Clark, R. I. & Walker, D. W. Rapamycin modulates tissue aging and lifespan independently of the gut microbiota in Drosophila. *Sci Rep* **9**, 7824, doi:10.1038/s41598-019-44106-5 (2019).
- Berger, Z. *et al.* Rapamycin alleviates toxicity of different aggregate-prone proteins. *Hum Mol Genet* **15**, 433-442, doi:10.1093/hmg/ddi458 (2006).

1121	85	Audesse, A. J. et al. FOXO3 directly regulates an autophagy network to functionally regulate
1122		proteostasis in adult neural stem cells. PLoS Genet 15, e1008097,
1123		doi:10.1371/journal.pgen.1008097 (2019).

- Leeman, D. S. *et al.* Lysosome activation clears aggregates and enhances quiescent neural stem cell activation during aging. *Science* **359**, 1277-1283, doi:10.1126/science.aag3048 (2018).
- Garcia-Prat, L. *et al.* Autophagy maintains stemness by preventing senescence. *Nature* **529**, 37-42, doi:10.1038/nature16187 (2016).
- Kuma, A. *et al.* The role of autophagy during the early neonatal starvation period. *Nature* **432**, 1032-1036, doi:10.1038/nature03029 (2004).
- Yang, Z., Huang, J., Geng, J., Nair, U. & Klionsky, D. J. Atg22 recycles amino acids to link the degradative and recycling functions of autophagy. *Mol Biol Cell* **17**, 5094-5104, doi:10.1091/mbc.e06-06-0479 (2006).
- Suzuki, S. W., Onodera, J. & Ohsumi, Y. Starvation induced cell death in autophagy-defective yeast mutants is caused by mitochondria dysfunction. *PLoS One* **6**, e17412, doi:10.1371/journal.pone.0017412 (2011).
- Ha, J., Guan, K. L. & Kim, J. AMPK and autophagy in glucose/glycogen metabolism. *Mol Aspects Med* **46**, 46-62, doi:10.1016/j.mam.2015.08.002 (2015).
- 1139 92 Adeva-Andany, M. M., Gonzalez-Lucan, M., Donapetry-Garcia, C., Fernandez-Fernandez, C. & 1140 Ameneiros-Rodriguez, E. Glycogen metabolism in humans. *BBA Clin* **5**, 85-100, doi:10.1016/j.bbacli.2016.02.001 (2016).
- 1142 93 Yao, W. *et al.* Atg11 is required for initiation of glucose starvation-induced autophagy. 1143 *Autophagy*, 1-13, doi:10.1080/15548627.2020.1719724 (2020).
- Jiang, S., Wells, C. D. & Roach, P. J. Starch-binding domain-containing protein 1 (Stbd1) and glycogen metabolism: Identification of the Atg8 family interacting motif (AIM) in Stbd1 required for interaction with GABARAPL1. *Biochem Biophys Res Commun* **413**, 420-425, doi:10.1016/j.bbrc.2011.08.106 (2011).
- Weber, C. A. *et al.* beta-Oxidation and autophagy are critical energy providers during acute glucose depletion in Saccharomyces cerevisiae. *Proc Natl Acad Sci U S A* **117**, 12239-12248, doi:10.1073/pnas.1913370117 (2020).
- Kim, K. A. *et al.* High glucose condition induces autophagy in endothelial progenitor cells contributing to angiogenic impairment. *Biol Pharm Bull* **37**, 1248-1252, doi:10.1248/bpb.b14-00172 (2014).
- 1154 97 Disease, A. W. G. o. M. o. P. *et al.* Pompe disease diagnosis and management guideline. 1155 *Genet Med* **8**, 267-288, doi:10.1097/01.gim.0000218152.87434.f3 (2006).
- Kishnani, P. S. *et al.* Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology* 68, 99-109, doi:10.1212/01.wnl.0000251268.41188.04 (2007).
- Duran, J., Gruart, A., Garcia-Rocha, M., Delgado-Garcia, J. M. & Guinovart, J. J. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Hum Mol Genet 23, 3147-3156, doi:10.1093/hmg/ddu024 (2014).
- 1162 100 Singh, R. *et al.* Autophagy regulates lipid metabolism. *Nature* **458**, 1131-1135, doi:10.1038/nature07976 (2009).
- 1164 101 Ward, C. *et al.* Autophagy, lipophagy and lysosomal lipid storage disorders. *Biochim Biophys Acta* **1861**, 269-284, doi:10.1016/j.bbalip.2016.01.006 (2016).
- 1166 102 Kaushik, S. & Cuervo, A. M. Degradation of lipid droplet-associated proteins by chaperone-1167 mediated autophagy facilitates lipolysis. *Nat Cell Biol* **17**, 759-770, doi:10.1038/ncb3166 1168 (2015).
- Goeritzer, M. *et al.* Active autophagy but not lipophagy in macrophages with defective lipolysis. *Biochim Biophys Acta* **1851**, 1304-1316, doi:10.1016/j.bbalip.2015.06.005 (2015).
- 1171 104 Kiffin, R. *et al.* Altered dynamics of the lysosomal receptor for chaperone-mediated autophagy with age. *J Cell Sci* **120**, 782-791, doi:10.1242/jcs.001073 (2007).

- 1173 105 Palikaras, K. *et al.* Ectopic fat deposition contributes to age-associated pathology in Caenorhabditis elegans. *J Lipid Res* **58**, 72-80, doi:10.1194/jlr.M069385 (2017).
- 1175 106 Stranks, A. J. *et al.* Autophagy Controls Acquisition of Aging Features in Macrophages. *J Innate Immun* **7**, 375-391, doi:10.1159/000370112 (2015).
- 1177 Lapierre, L. R., Melendez, A. & Hansen, M. Autophagy links lipid metabolism to longevity in C. elegans. *Autophagy* **8**, 144-146, doi:10.4161/auto.8.1.18722 (2012).
- 1179 108 Folick, A. *et al.* Aging. Lysosomal signaling molecules regulate longevity in Caenorhabditis elegans. *Science* **347**, 83-86, doi:10.1126/science.1258857 (2015).
- Lapierre, L. R., Gelino, S., Melendez, A. & Hansen, M. Autophagy and lipid metabolism coordinately modulate life span in germline-less C. elegans. *Curr Biol* **21**, 1507-1514, doi:10.1016/j.cub.2011.07.042 (2011).
- 2 Zhang, T. *et al.* SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity. *Cell Death Differ* **27**, 329-344, doi:10.1038/s41418-019-0356-z (2020).
- Fang, E. F. *et al.* NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome. *Nat Commun* **10**, 5284, doi:10.1038/s41467-019-13172-8 (2019).
- 1189 112 Baur, J. A. *et al.* Resveratrol improves health and survival of mice on a high-calorie diet. 1190 *Nature* **444**, 337-342, doi:10.1038/nature05354 (2006).
- Ding, W. X., Li, M. & Yin, X. M. Selective taste of ethanol-induced autophagy for mitochondria and lipid droplets. *Autophagy* **7**, 248-249, doi:10.4161/auto.7.2.14347 (2011).
- 1193 114 Kounakis, K., Chaniotakis, M., Markaki, M. & Tavernarakis, N. Emerging Roles of Lipophagy in Health and Disease. *Front Cell Dev Biol* **7**, 185, doi:10.3389/fcell.2019.00185 (2019).
- 1195 115 Chao, X. *et al.* Impaired TFEB-Mediated Lysosome Biogenesis and Autophagy Promote 1196 Chronic Ethanol-Induced Liver Injury and Steatosis in Mice. *Gastroenterology* **155**, 865-879 e812, doi:10.1053/j.gastro.2018.05.027 (2018).
- Hernandez-Gea, V. *et al.* Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology* **142**, 938-946, doi:10.1053/j.gastro.2011.12.044 (2012).
- 1201 117 Riffelmacher, T. *et al.* Autophagy-Dependent Generation of Free Fatty Acids Is Critical for Normal Neutrophil Differentiation. *Immunity* **47**, 466-480 e465, doi:10.1016/j.immuni.2017.08.005 (2017).
- 1204 118 Kawane, K., Motani, K. & Nagata, S. DNA degradation and its defects. *Cold Spring Harb* 1205 *Perspect Biol* **6**, doi:10.1101/cshperspect.a016394 (2014).
- 1206 119 Houseley, J. & Tollervey, D. The many pathways of RNA degradation. *Cell* **136**, 763-776, doi:10.1016/j.cell.2009.01.019 (2009).
- 1208 Buchan, J. R., Kolaitis, R. M., Taylor, J. P. & Parker, R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. *Cell* **153**, 1461-1474, doi:10.1016/j.cell.2013.05.037 (2013).
- 1211 Guo, H. *et al.* Autophagy supports genomic stability by degrading retrotransposon RNA. *Nat Commun* **5**, 5276, doi:10.1038/ncomms6276 (2014).
- 1213 122 Fujiwara, Y. *et al.* Direct uptake and degradation of DNA by lysosomes. *Autophagy* **9**, 1167-1214 1171, doi:10.4161/auto.24880 (2013).
- Fujiwara, Y. *et al.* Discovery of a novel type of autophagy targeting RNA. *Autophagy* **9**, 403-409, doi:10.4161/auto.23002 (2013).
- 1217 124 Aizawa, S. *et al.* Lysosomal membrane protein SIDT2 mediates the direct uptake of DNA by lysosomes. *Autophagy* **13**, 218-222, doi:10.1080/15548627.2016.1248019 (2017).
- 1219 125 Aizawa, S. *et al.* Lysosomal putative RNA transporter SIDT2 mediates direct uptake of RNA by 1220 lysosomes. *Autophagy* **12**, 565-578, doi:10.1080/15548627.2016.1145325 (2016).
- 1221 126 Sliter, D. A. *et al.* Parkin and PINK1 mitigate STING-induced inflammation. *Nature* **561**, 258-1222 262, doi:10.1038/s41586-018-0448-9 (2018).
- 1223 127 West, A. P. *et al.* Mitochondrial DNA stress primes the antiviral innate immune response. 1224 *Nature* **520**, 553-557, doi:10.1038/nature14156 (2015).

- 1225 128 Dan, X. *et al.* DNA damage invokes mitophagy through a pathway involving Spata18. *Nucleic Acids Res* **48**, 6611-6623, doi:10.1093/nar/gkaa393 (2020).
- Hopfner, K. P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. *Nat Rev Mol Cell Biol* **21**, 501-521, doi:10.1038/s41580-020-0244-x (2020).
- 130 Johansen, T. & Lamark, T. Selective Autophagy: ATG8 Family Proteins, LIR Motifs and Cargo Receptors. *J Mol Biol* **432**, 80-103, doi:10.1016/j.jmb.2019.07.016 (2020).
- 1231 Pickles, S., Vigie, P. & Youle, R. J. Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance. *Curr Biol* **28**, R170-R185, doi:10.1016/j.cub.2018.01.004 (2018).
- 1233 Le Guerroue, F. *et al.* Autophagosomal Content Profiling Reveals an LC3C-Dependent
 1234 Piecemeal Mitophagy Pathway. *Mol Cell* **68**, 786-796 e786, doi:10.1016/j.molcel.2017.10.029
 1235 (2017).
- 1236 133 McLelland, G. L., Lee, S. A., McBride, H. M. & Fon, E. A. Syntaxin-17 delivers PINK1/parkin-1237 dependent mitochondrial vesicles to the endolysosomal system. *J Cell Biol* **214**, 275-291, 1238 doi:10.1083/jcb.201603105 (2016).
- 1239 134 Melentijevic, I. *et al.* C. elegans neurons jettison protein aggregates and mitochondria under neurotoxic stress. *Nature* **542**, 367-371, doi:10.1038/nature21362 (2017).
- 1241 135 Nicolas-Avila, J. A. *et al.* A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart. *Cell* **183**, 94-109 e123, doi:10.1016/j.cell.2020.08.031 (2020).
- 1243 136 Cornelissen, T. *et al.* Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila. *Elife* **7**, doi:10.7554/eLife.35878 (2018).
- 1245 137 Sun, N. *et al.* Measuring In Vivo Mitophagy. *Mol Cell* **60**, 685-696, 1246 doi:10.1016/j.molcel.2015.10.009 (2015).
- 1247 138 Fang, E. F. *et al.* Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. *Nat Neurosci* **22**, 401-412, doi:10.1038/s41593-018-0332-9 (2019).
- 1250 139 Pickrell, A. M. & Youle, R. J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron* **85**, 257-273, doi:10.1016/j.neuron.2014.12.007 (2015).
- 1252 140 Palikaras, K., Lionaki, E. & Tavernarakis, N. Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans. *Nature* **521**, 525-528, doi:10.1038/nature14300 (2015).
- 1255 141 McWilliams, T. G. *et al.* Basal Mitophagy Occurs Independently of PINK1 in Mouse Tissues of High Metabolic Demand. *Cell Metab* **27**, 439-449 e435, doi:10.1016/j.cmet.2017.12.008 1257 (2018).
- 1258 142 Fang, E. F. *et al.* Tomatidine enhances lifespan and healthspan in C. elegans through mitophagy induction via the SKN-1/Nrf2 pathway. *Sci Rep* **7**, 46208, doi:10.1038/srep46208 1260 (2017).
- Du, F. *et al.* PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. *Brain* **140**, 3233-3251, doi:10.1093/brain/awx258 (2017).
- 1263 144 Fang, E. F. *et al.* NAD(+) Replenishment Improves Lifespan and Healthspan in Ataxia 1264 Telangiectasia Models via Mitophagy and DNA Repair. *Cell Metab* **24**, 566-581, doi:10.1016/j.cmet.2016.09.004 (2016).
- 1266 145 Mochida, K. *et al.* Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus. *Nature* **522**, 359-362, doi:10.1038/nature14506 (2015).
- 1268 146 Hubner, C. A. & Dikic, I. ER-phagy and human diseases. *Cell Death Differ* **27**, 833-842, doi:10.1038/s41418-019-0444-0 (2020).
- 1270 147 Park, Y. E. *et al.* Autophagic degradation of nuclear components in mammalian cells. *Autophagy* **5**, 795-804, doi:10.4161/auto.8901 (2009).
- 1272 148 Dou, Z. *et al.* Autophagy mediates degradation of nuclear lamina. *Nature* **527**, 105-109, doi:10.1038/nature15548 (2015).
- 1274 149 Papadopoulos, C., Kravic, B. & Meyer, H. Repair or Lysophagy: Dealing with Damaged Lysosomes. *J Mol Biol* **432**, 231-239, doi:10.1016/j.jmb.2019.08.010 (2020).

- 1276 Li, Y. *et al.* The lysosomal membrane protein SCAV-3 maintains lysosome integrity and adult longevity. *J Cell Biol* **215**, 167-185, doi:10.1083/jcb.201602090 (2016).
- 1278 151 Vesosky, B. & Turner, J. The influence of age on immunity to infection with Mycobacterium tuberculosis. *Immunol Rev* **205**, 229-243, doi:10.1111/j.0105-2896.2005.00257.x (2005).
- 1280 152 Papadopoulos, C. & Meyer, H. Detection and Clearance of Damaged Lysosomes by the Endo-1281 Lysosomal Damage Response and Lysophagy. *Curr Biol* **27**, R1330-R1341, 1282 doi:10.1016/j.cub.2017.11.012 (2017).
- 1283 153 Gomez-Sintes, R., Ledesma, M. D. & Boya, P. Lysosomal cell death mechanisms in aging. 1284 Ageing Res Rev **32**, 150-168, doi:10.1016/j.arr.2016.02.009 (2016).
- 1285 154 Reggio, A., Buonomo, V. & Grumati, P. Eating the unknown: Xenophagy and ER-phagy are cytoprotective defenses against pathogens. *Exp Cell Res* **396**, 112276, doi:10.1016/j.yexcr.2020.112276 (2020).
- Levine, B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. *Cell* **120**, 159-162, doi:10.1016/j.cell.2005.01.005 (2005).
- 1290 156 Rikihisa, Y. Glycogen Autophagosomes in Polymorphonuclear Leukocytes Induced by Rickettsiae. *Anat Rec* **208**, 319-327, doi:DOI 10.1002/ar.1092080302 (1984).
- 1292 157 Rich, K. A., Burkett, C. & Webster, P. Cytoplasmic bacteria can be targets for autophagy. *Cell Microbiol* **5**, 455-468, doi:DOI 10.1046/j.1462-5822.2003.00292.x (2003).
- 1294 158 Nakagawa, I. *et al.* Autophagy defends cells against invading group A Streptococcus. *Science* 1295 **306**, 1037-1040, doi:10.1126/science.1103966 (2004).
- 1296 159 Gutierrez, M. G. *et al.* Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. *Cell* **119**, 753-766, doi:10.1016/j.cell.2004.11.038 (2004).
- 1299 160 Kimmey, J. M. & Stallings, C. L. Bacterial Pathogens versus Autophagy: Implications for Therapeutic Interventions. *Trends Mol Med* **22**, 1060-1076, doi:10.1016/j.molmed.2016.10.008 (2016).
- 1302 161 Upadhyay, S., Mittal, E. & Philips, J. A. Tuberculosis and the art of macrophage manipulation. 1303 Pathog Dis **76**, doi:10.1093/femspd/fty037 (2018).
- 1304 162 Watson, R. O. *et al.* The Cytosolic Sensor cGAS Detects Mycobacterium tuberculosis DNA to Induce Type I Interferons and Activate Autophagy. *Cell Host Microbe* **17**, 811-819, doi:10.1016/j.chom.2015.05.004 (2015).
- 1307 163 Franco, L. H. *et al.* The Ubiquitin Ligase Smurf1 Functions in Selective Autophagy of Mycobacterium tuberculosis and Anti-tuberculous Host Defense. *Cell Host Microbe* **21**, 59-72, doi:10.1016/j.chom.2016.11.002 (2017).
- 1310 164 Bah, A. & Vergne, I. Macrophage Autophagy and Bacterial Infections. *Front Immunol* **8**, 1483, doi:10.3389/fimmu.2017.01483 (2017).
- 1312 Jayaswal, S. *et al.* Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. *PLoS Pathog* **6**, e1000839, doi:10.1371/journal.ppat.1000839 (2010).
- 1315 166 Kim, J. J. *et al.* Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. *Cell Host Microbe* **11**, 457-468, doi:10.1016/j.chom.2012.03.008 (2012).
- 1318 167 Watson, R. O., Manzanillo, P. S. & Cox, J. S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. *Cell* **150**, 803-815, doi:10.1016/j.cell.2012.06.040 (2012).
- Wang, J. *et al.* MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. *PLoS Pathog* **9**, e1003697, doi:10.1371/journal.ppat.1003697 (2013).
- 1323 169 Liang, X. H. *et al.* Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. *J Virol* **72**, 8586-8596, doi:10.1128/JVI.72.11.8586-8596.1998 (1998).
- Orvedahl, A. *et al.* Autophagy protects against Sindbis virus infection of the central nervous system. *Cell Host Microbe* **7**, 115-127, doi:10.1016/j.chom.2010.01.007 (2010).

- Orvedahl, A. *et al.* HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. *Cell Host Microbe* **1**, 23-35, doi:10.1016/j.chom.2006.12.001 (2007).
- 1329 172 Mijaljica, D. & Klionsky, D. J. Autophagy/virophagy: a "disposal strategy" to combat COVID-1330 19. *Autophagy*, 1-2, doi:10.1080/15548627.2020.1782022 (2020).
- Shojaei, S., Suresh, M., Klionsky, D. J., Labouta, H. I. & Ghavami, S. Autophagy and SARS-CoV-1332 2 infection: A possible smart targeting of the autophagy pathway. *Virulence* **11**, 805-810, 1333 doi:10.1080/21505594.2020.1780088 (2020).
- 1334 174 Carmona-Gutierrez, D. *et al.* Digesting the crisis: autophagy and coronaviruses. *Microb Cell* **7**, 1335 119-128, doi:10.15698/mic2020.05.715 (2020).
- 1336 175 Choi, J. *et al.* The parasitophorous vacuole membrane of Toxoplasma gondii is targeted for disruption by ubiquitin-like conjugation systems of autophagy. *Immunity* **40**, 924-935, doi:10.1016/j.immuni.2014.05.006 (2014).
- Ghartey-Kwansah, G. *et al.* Autophagy in the control and pathogenesis of parasitic infections. *Cell Biosci* **10**, 101, doi:10.1186/s13578-020-00464-6 (2020).
- 1341 177 O'Driscoll, M. *et al.* Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*, doi:10.1038/s41586-020-2918-0 (2020).
- 1343 178 Gelino, S. *et al.* Intestinal Autophagy Improves Healthspan and Longevity in C. elegans during Dietary Restriction. *PLoS Genet* **12**, e1006135, doi:10.1371/journal.pgen.1006135 (2016).
- Minnerly, J., Zhang, J., Parker, T., Kaul, T. & Jia, K. The cell non-autonomous function of ATG-1346 18 is essential for neuroendocrine regulation of Caenorhabditis elegans lifespan. *PLoS Genet* 1347 **13**, e1006764, doi:10.1371/journal.pgen.1006764 (2017).
- 1348 180 Bai, H., Kang, P., Hernandez, A. M. & Tatar, M. Activin signaling targeted by insulin/dFOXO regulates aging and muscle proteostasis in Drosophila. *PLoS Genet* **9**, e1003941, doi:10.1371/journal.pgen.1003941 (2013).
- 1351 181 Carnio, S. *et al.* Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. *Cell Rep* **8**, 1509-1521, doi:10.1016/j.celrep.2014.07.061 (2014).
- 1354 182 Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol* **14**, R115, doi:10.1186/gb-2013-14-10-r115 (2013).
- Dong, S. *et al.* Chaperone-mediated autophagy sustains haematopoietic stem-cell function. *Nature* **591**, 117-123, doi:10.1038/s41586-020-03129-z (2021).
- Bourdenx, M. *et al.* Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. *Cell* **184**, 2696-2714 e2625, doi:10.1016/j.cell.2021.03.048 (2021).
- 1360 185 Lautrup, S., Sinclair, D. A., Mattson, M. P. & Fang, E. F. NAD(+) in Brain Aging and Neurodegenerative Disorders. *Cell Metab* **30**, 630-655, doi:10.1016/j.cmet.2019.09.001 (2019).
- 1363 186 Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol* **14**, 576-590, doi:10.1038/s41574-018-0059-4 (2018).
- 1366 187 Medzhitov, R. Origin and physiological roles of inflammation. *Nature* **454**, 428-435, doi:10.1038/nature07201 (2008).
- 1368 188 Riffelmacher, T., Richter, F. C. & Simon, A. K. Autophagy dictates metabolism and differentiation of inflammatory immune cells. *Autophagy* **14**, 199-206, doi:10.1080/15548627.2017.1362525 (2018).
- Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. *Nat Rev Immunol* **19**, 477-489, doi:10.1038/s41577-019-0165-0 (2019).
- 1374 190 Sun, Q., Fan, J., Billiar, T. R. & Scott, M. J. Inflammasome and autophagy regulation a twoway street. *Mol Med* **23**, 188-195, doi:10.2119/molmed.2017.00077 (2017).
- 1376 191 Menzies, F. M. *et al.* Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. *Neuron* **93**, 1015-1034, doi:10.1016/j.neuron.2017.01.022 (2017).

- 1378 192 Rubinsztein, D. C., Codogno, P. & Levine, B. Autophagy modulation as a potential therapeutic 1379 target for diverse diseases. Nat Rev Drug Discov 11, 709-730, doi:10.1038/nrd3802 (2012).
- 1380 193 Wood, J. G. et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. 1381 Nature 430, 686-689, doi:10.1038/nature02789 (2004).
- 1382 194 Morselli, E. et al. Spermidine and resveratrol induce autophagy by distinct pathways 1383 converging on the acetylproteome. J Cell Biol 192, 615-629, doi:10.1083/jcb.201008167 1384 (2011).
- 1385 Pietrocola, F. et al. Spermidine induces autophagy by inhibiting the acetyltransferase EP300. 195 1386 *Cell Death Differ* **22**, 509-516, doi:10.1038/cdd.2014.215 (2015).
- 1387 196 Madeo, F., Eisenberg, T., Pietrocola, F. & Kroemer, G. Spermidine in health and disease. 1388 Science 359, doi:10.1126/science.aan2788 (2018).
- 1389 197 Eisenberg, T. et al. Cardioprotection and lifespan extension by the natural polyamine 1390 spermidine. Nat Med 22, 1428-1438, doi:10.1038/nm.4222 (2016).
- 1391 198 Zhang, H. et al. Polyamines Control eIF5A Hypusination, TFEB Translation, and Autophagy to 1392 Reverse B Cell Senescence. Mol Cell 76, 110-125 e119, doi:10.1016/j.molcel.2019.08.005 1393 (2019).
- 1394 199 Eisenberg, T. et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 1395 11, 1305-1314, doi:10.1038/ncb1975 (2009).
- 1396 Song, H. L., Demirev, A. V., Kim, N. Y., Kim, D. H. & Yoon, S. Y. Ouabain activates transcription 200 1397 factor EB and exerts neuroprotection in models of Alzheimer's disease. Mol Cell Neurosci 95, 1398 13-24, doi:10.1016/j.mcn.2018.12.007 (2019).
- 1399 201 Huang, R. et al. Deacetylation of nuclear LC3 drives autophagy initiation under starvation. 1400 Mol Cell 57, 456-466, doi:10.1016/j.molcel.2014.12.013 (2015).
- 1401 202 Lee, I. H. et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of 1402 autophagy. Proc Natl Acad Sci U S A 105, 3374-3379, doi:10.1073/pnas.0712145105 (2008).
- 1403 203 Fang, E. F. Mitophagy and NAD(+) inhibit Alzheimer disease. Autophagy 15, 1112-1114, 1404 doi:10.1080/15548627.2019.1596497 (2019).
- 1405 204 Mouchiroud, L. et al. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of 1406 Mitochondrial UPR and FOXO Signaling. Cell 154, 430-441, doi:10.1016/j.cell.2013.06.016 1407 (2013).
- 1408 205 Zhang, H. et al. NAD(+) repletion improves mitochondrial and stem cell function and 1409 enhances life span in mice. Science 352, 1436-1443, doi:10.1126/science.aaf2693 (2016).
- 1410 206 Mitchell, S. J. et al. Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice. 1411 Cell Metab 27, 667-676 e664, doi:10.1016/j.cmet.2018.02.001 (2018).
- 1412 207 Ryu, D. et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases 1413 muscle function in rodents. Nat Med 22, 879-888, doi:10.1038/nm.4132 (2016).
- 1414 208 Andreux, P. A. et al. The mitophagy activator urolithin A is safe and induces a molecular 1415 signature of improved mitochondrial and cellular health in humans. Nature Metab 1, 593-603 1416 (2019).
- 1417 209 Escobar, K. A., Cole, N. H., Mermier, C. M. & VanDusseldorp, T. A. Autophagy and aging: 1418 Maintaining the proteome through exercise and caloric restriction. Aging Cell 18, e12876, 1419 doi:10.1111/acel.12876 (2019).
- 1420 210 de Cabo, R. & Mattson, M. P. Effects of Intermittent Fasting on Health, Aging, and Disease. N 1421 Engl J Med 381, 2541-2551, doi:10.1056/NEJMra1905136 (2019).
- 1422 211 Alexander-Floyd, J. et al. Unexpected cell type-dependent effects of autophagy on 1423 polyglutamine aggregation revealed by natural genetic variation in C. elegans. BMC Biol 18, 1424 18, doi:10.1186/s12915-020-0750-5 (2020).
- 1425 Bjedov, I. et al. Fine-tuning autophagy maximises lifespan and is associated with changes in 212 1426 mitochondrial gene expression in Drosophila. PLoS Genet 16, e1009083, 1427 doi:10.1371/journal.pgen.1009083 (2020).

1428	213	Mulcahy Levy, J. M. & Thorburn, A. Autophagy in cancer: moving from understanding
1429		mechanism to improving therapy responses in patients. Cell Death Differ 27, 843-857,
1430		doi:10.1038/s41418-019-0474-7 (2020).

- 1431 214 Park, C. & Cuervo, A. M. Selective autophagy: talking with the UPS. *Cell Biochem Biophys* **67**, 1432 3-13, doi:10.1007/s12013-013-9623-7 (2013).
- 1433 215 Yang, S. *et al.* Pancreatic cancers require autophagy for tumor growth. *Genes Dev* **25**, 717-1434 729, doi:10.1101/gad.2016111 (2011).
- 1435 216 Piffoux, M., Eriau, E. & Cassier, P. A. Autophagy as a therapeutic target in pancreatic cancer. 1436 Br J Cancer **124**, 333-344, doi:10.1038/s41416-020-01039-5 (2021).
- Matsuura, A., Tsukada, M., Wada, Y. & Ohsumi, Y. Apg1p, a novel protein kinase required for the autophagic process in Saccharomyces cerevisiae. *Gene* **192**, 245-250, doi:10.1016/s0378-1119(97)00084-x (1997).
- Alvers, A. L. *et al.* Autophagy is required for extension of yeast chronological life span by rapamycin. *Autophagy* **5**, 847-849, doi:10.4161/auto.8824 (2009).
- Rana, A. *et al.* Promoting Drp1-mediated mitochondrial fission in midlife prolongs healthy lifespan of Drosophila melanogaster. *Nat Commun* **8**, 448, doi:10.1038/s41467-017-00525-4 (2017).
- Velikkakath, A. K., Nishimura, T., Oita, E., Ishihara, N. & Mizushima, N. Mammalian Atg2 proteins are essential for autophagosome formation and important for regulation of size and distribution of lipid droplets. *Mol Biol Cell* **23**, 896-909, doi:10.1091/mbc.E11-09-0785 (2012).
- 1448 221 Xu, P. *et al.* Atg2, Atg9 and Atg18 in mitochondrial integrity, cardiac function and healthspan in Drosophila. *J Mol Cell Cardiol* **127**, 116-124, doi:10.1016/j.yjmcc.2018.12.006 (2019).
- Maruyama, T. & Noda, N. N. Autophagy-regulating protease Atg4: structure, function, regulation and inhibition. *J Antibiot (Tokyo)*, doi:10.1038/ja.2017.104 (2017).
- Yang, J. *et al.* MiR-34 modulates Caenorhabditis elegans lifespan via repressing the autophagy gene atg9. *Age (Dordr)* **35**, 11-22, doi:10.1007/s11357-011-9324-3 (2013).
- 1454 224 Reggiori, F. & Klionsky, D. J. Autophagosomes: biogenesis from scratch? *Curr Opin Cell Biol* 1455 **17**, 415-422, doi:10.1016/j.ceb.2005.06.007 (2005).
- Ruckenstuhl, C. *et al.* Lifespan extension by methionine restriction requires autophagydependent vacuolar acidification. *PLoS Genet* **10**, e1004347, doi:10.1371/journal.pgen.1004347 (2014).
- Bjedov, I. *et al.* Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. *Cell Metab* **11**, 35-46, doi:10.1016/j.cmet.2009.11.010 (2010).
- Jia, K. & Levine, B. Autophagy is required for dietary restriction-mediated life span extension in C. elegans. *Autophagy* **3**, 597-599, doi:10.4161/auto.4989 (2007).
- 1463 228 Hars, E. S. *et al.* Autophagy regulates ageing in C. elegans. *Autophagy* **3**, 93-95, doi:10.4161/auto.3636 (2007).
- He, C. & Klionsky, D. J. Regulation mechanisms and signaling pathways of autophagy. *Annu Rev Genet* **43**, 67-93, doi:10.1146/annurev-genet-102808-114910 (2009).
- Walczak, M. & Martens, S. Dissecting the role of the Atg12-Atg5-Atg16 complex during autophagosome formation. *Autophagy* **9**, 424-425, doi:10.4161/auto.22931 (2013).
- Teter, S. A. *et al.* Degradation of lipid vesicles in the yeast vacuole requires function of Cvt17, a putative lipase. *J Biol Chem* **276**, 2083-2087, doi:10.1074/jbc.C000739200 (2001).
- Tang, F. *et al.* A life-span extending form of autophagy employs the vacuole-vacuole fusion machinery. *Autophagy* **4**, 874-886, doi:10.4161/auto.6556 (2008).
- Rieter, E. *et al.* Atg18 function in autophagy is regulated by specific sites within its betapropeller. *J Cell Sci* **126**, 593-604, doi:10.1242/jcs.115725 (2013).
- 1475 234 McQuary, P. R. *et al.* C. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan Extension. *Cell Rep* **14**, 2059-2067, doi:10.1016/j.celrep.2016.02.012 (2016).
- Narendra, D., Tanaka, A., Suen, D. F. & Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J Cell Biol* **183**, 795-803, doi:10.1083/jcb.200809125 (2008).

1480	236	Rana, A., Rera, M. & Walker, D. W. Parkin overexpression during aging reduces
1481		proteotoxicity, alters mitochondrial dynamics, and extends lifespan. Proc Natl Acad Sci U S A
1482		110, 8638-8643, doi:10.1073/pnas.1216197110 (2013).
1483	237	Zhuang, N., Li, L., Chen, S. & Wang, T. PINK1-dependent phosphorylation of PINK1 and Parkin
1484		is essential for mitochondrial quality control. Cell Death Dis 7, e2501,
1485		doi:10.1038/cddis.2016.396 (2016).
1486	238	Schiavi, A. et al. Iron-Starvation-Induced Mitophagy Mediates Lifespan Extension upon
1487		Mitochondrial Stress in C. elegans. Curr Biol 25, 1810-1822, doi:10.1016/j.cub.2015.05.059
1488		(2015).
1489	239	Johansen, T. & Lamark, T. Selective autophagy mediated by autophagic adapter proteins.
1490		Autophagy 7 , 279-296, doi:10.4161/auto.7.3.14487 (2011).
1491	240	Parekh, V. V. et al. Autophagy-related protein Vps34 controls the homeostasis and function
1492		of antigen cross-presenting CD8alpha(+) dendritic cells. Proc Natl Acad Sci U S A 114, E6371-
1493		E6380, doi:10.1073/pnas.1706504114 (2017).
1494	241	Cabreiro, F. et al. Metformin retards aging in C. elegans by altering microbial folate and
1495		methionine metabolism. <i>Cell</i> 153 , 228-239, doi:10.1016/j.cell.2013.02.035 (2013).
1496	242	Partridge, L., Fuentealba, M. & Kennedy, B. K. The quest to slow ageing through drug
1497		discovery. <i>Nat Rev Drug Discov</i> 19 , 513-532, doi:10.1038/s41573-020-0067-7 (2020).
1498	243	Fivenson, E. M. et al. Mitophagy in neurodegeneration and aging. Neurochem Int 109, 202-
1499		209, doi:10.1016/j.neuint.2017.02.007 (2017).
1500	244	Honda, Y., Tanaka, M. & Honda, S. Trehalose extends longevity in the nematode
1501		Caenorhabditis elegans. Aging Cell 9, 558-569, doi:10.1111/j.1474-9726.2010.00582.x (2010).
1502	245	Shi, D. et al. The precursor of PI(3,4,5)P3 alleviates aging by activating daf-18(Pten) and
1503		independent of daf-16. Nat Commun 11, 4496, doi:10.1038/s41467-020-18280-4 (2020).

Supplementary Table 1. Progeria syndromes and neurodegenerative diseases show altered autophagy


Categories	Disease	Relations to autophagy
Accelerated ageing	Ataxia Telangiectasia	ATM participates in both autophagy and mitophagy; <i>Atm</i> mutation leads to defective mitophagy ^{1,2} .
	Cockayne syndrome	CSB participates in autophagy/mitophagy ^{1,3} .
	Fanconi Anemia	Dysfunction of different Fanconi Anemia protein members lead to dysfunctional xenophagy and mitophagy ⁴ .
	Hutchinson-Gilford syndrome	p62 interacts with progerin and boosting autophagy with rapamycin improves clearance of progerin ⁵ .
	Werner syndrome	Werner participates in mitophagy ⁶ .
	Xeroderma Pigmentosum	XPA participates in both autophagy and mitophagy; XPA mutation leads to defective mitophagy¹.
Neurodegeneration	Alzheimer's Disease (AD)	The familial AD gene <i>PS1</i> mutant disrupts autophagy and lysosomal proteolysis ⁷ . Impaired mitophagy in postmortem brain tissues from AD patients and in both Aβ and Tau animal models of AD ⁸ . Proteins involved in autophagy or mitophagy, including PINK1, TBK1 (p-), ULK1 (p-), OPTN, BECN1/Beclin 1, AMBRA1, Bcl2L13, FUNDC1, MUL1, BNIP3L/NIX, were reduced in some AD patient samples (postmortem brain tissue or IPSC-derived cortical neurons) ⁸ . Reduced BAG-3 in the entorhinal cortex of AD ⁹ .
	Parkinson's Disease (PD)	(M) α -Synuclein, from Lewy bodies, affect the localization of ATG9 ¹⁰ ; α -Synuclein is also capable of impairing the chaperone-mediated autophagy pathway ¹¹ ; Overexpression of ATG6 ameliorates the aggregation of α -syn ¹² ; <i>PINK1</i> and <i>PARK2</i> mutations lead to familial PD (reviewed in ¹³) .
	Amyotrophic Lateral Sclerosis (ALS)	(H) Mutations of many autophagy genes, such as <i>TBK1</i> and <i>SQSTM1</i> , link to ALS (reviewed in ¹³)
	Frontotemporal Dementia (FTD)	(H) Mutations of many autophagy genes, such <i>TBK1</i> and <i>SQSTM1</i> , link to ALS (reviewed in ¹³)
	Huntington's Disease (HD)	ATG7 variants may pay a role in the age of onset ^{14,15} . Cargo recognition is disrupted ¹⁶ . Huntingtin mutant may be sequestering ATG6 ¹⁷ . Absence of Alfy disrupts autophagy and accelerates aggregation ¹⁸ .
	Autosomal Recessive Juvenile Parkinsonism (ARJP)	(H) PARK2 mutation plays a causative role ¹⁹ .
	Ataxia	(H) ATG5 mutation leads to ataxia ²⁰ .
	Hereditary Spastic Paraparesis (HSP)	(H) TECPR2 mutation causes some types of HSP ²¹ . SPG15 mutation may cause some types of HSP ²² .
	Lafora Disease	There are correlations between lack of laforin and an increase in TOR activity, inhibiting autophagy ²³ .
	SENDA & BPAN	(H) WDR45 mutations have been suggested to cause it ^{24,25} .


Abbreviations: Ataxia Telangiectasia mutated (ATM), Mice (M), Cockayne Syndrome group B (CSB), Xeroderma Pigmentosum group A (XPA), Humans (H), ↑ (Overexpression), ↓ (Reduced expression), Static encephalopathy of childhood with neurodegeneration in adulthood (SENDA), Beta-propeller protein-associated neurodegeneration (BPAN).

References

- Fang, E. F. *et al.* Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. *Cell* **157**, 882-896, doi:10.1016/j.cell.2014.03.026 (2014).
- Fang, E. F. *et al.* NAD(+) Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair. *Cell Metab* **24**, 566-581, doi:10.1016/j.cmet.2016.09.004 (2016).
- Scheibye-Knudsen, M. *et al.* Cockayne syndrome group B protein prevents the accumulation of damaged mitochondria by promoting mitochondrial autophagy. *J Exp Med* **209**, 855-869, doi:10.1084/jem.20111721 (2012).
- Sumpter, R., Jr. *et al.* Fanconi Anemia Proteins Function in Mitophagy and Immunity. *Cell* **165**, 867-881, doi:10.1016/j.cell.2016.04.006 (2016).
- Cao, K. *et al.* Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. *Sci Transl Med* **3**, 89ra58, doi:10.1126/scitranslmed.3002346 (2011).
- Fang, E. F. *et al.* NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome. *Nat Commun* **10**, 5284, doi:10.1038/s41467-019-13172-8 (2019).
- Lee, J. H. *et al.* Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. *Cell* **141**, 1146-1158, doi:10.1016/j.cell.2010.05.008 (2010).
- Fang, E. F. *et al.* Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. *Nat Neurosci* **22**, 401-412, doi:10.1038/s41593-018-0332-9 (2019).
- 9 Fu, H. *et al.* A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. *Nat Neurosci* **22**, 47-56, doi:10.1038/s41593-018-0298-7 (2019).
- Winslow, A. R. *et al.* alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. *J Cell Biol* **190**, 1023-1037, doi:10.1083/jcb.201003122 (2010).
- Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. *Science* **305**, 1292-1295, doi:10.1126/science.1101738 (2004).
- Spencer, B. *et al.* Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. *J Neurosci* **29**, 13578-13588, doi:10.1523/JNEUROSCI.4390-09.2009 (2009).
- Lou, G. *et al.* Mitophagy and Neuroprotection. *Trends Mol Med,* doi:10.1016/j.molmed.2019.07.002 (2019).
- Metzger, S. *et al.* The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients. *PLoS One* **8**, e68951, doi:10.1371/journal.pone.0068951 (2013).
- Metzger, S. *et al.* Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. *Hum Genet* **128**, 453-459, doi:10.1007/s00439-010-0873-9 (2010).
- Martinez-Vicente, M. *et al.* Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. *Nat Neurosci* **13**, 567-576, doi:10.1038/nn.2528 (2010).
- Shibata, M. *et al.* Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. *J Biol Chem* **281**, 14474-14485, doi:10.1074/jbc.M600364200 (2006).
- Fox, L. M. *et al.* Huntington's Disease Pathogenesis Is Modified In Vivo by Alfy/Wdfy3 and Selective Macroautophagy. *Neuron* **105**, 813-821 e816, doi:10.1016/j.neuron.2019.12.003 (2020).

- Kitada, T. *et al.* Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* **392**, 605-608, doi:10.1038/33416 (1998).
- Kim, M. *et al.* Mutation in ATG5 reduces autophagy and leads to ataxia with developmental delay. *Elife* **5**, doi:10.7554/eLife.12245 (2016).
- Oz-Levi, D. *et al.* Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. *Am J Hum Genet* **91**, 1065-1072, doi:10.1016/j.ajhg.2012.09.015 (2012).
- Hanein, S. *et al.* Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. *Am J Hum Genet* **82**, 992-1002, doi:10.1016/j.ajhg.2008.03.004 (2008).
- Aguado, C. *et al.* Laforin, the most common protein mutated in Lafora disease, regulates autophagy. *Hum Mol Genet* **19**, 2867-2876, doi:10.1093/hmg/ddq190 (2010).
- Saitsu, H. *et al.* De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. *Nat Genet* **45**, 445-449, 449e441, doi:10.1038/ng.2562 (2013).
- Haack, T. B. *et al.* Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. *Am J Hum Genet* **91**, 1144-1149, doi:10.1016/j.ajhg.2012.10.019 (2012).





a. Core machinery of Macroautophagy

